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Abstract: The vertebrate immune system uses pattern recognition receptors (PRRs) to detect a large variety 
of molecular signatures (pathogen-associated molecular patterns, PAMPs) from a broad range of different 
invading pathogens. The PAMPs range in size from relatively small molecules, to others of intermediate size 
such as bacterial lipopolysaccharide, lipopeptides, and oligosaccharides, to macromolecules such as viral 
DNA, RNA, and pathogen-derived proteins such as flagellin. Underlying this functional diversity of PRRs is a 
surprisingly small number of structurally distinct protein folds that include leucine-rich repeats in Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs), the DExH box helicase domain in RIG-like receptors (RLRs), 
and C-type lectin domains (CTLDs) in the C-type lectins. Following PAMP recognition by the PRRs, down-
stream signaling pathways activate the innate immune system to respond to invading pathogenic organisms. 
The resulting stimulatory response is also vital for a balanced adaptive immune response to the pathogen, 
mediated by circulating antibodies and/or cytotoxic T cells. However, an aberrant stimulation of the innate 
immune system can also lead to excessive inflammatory and toxic stress responses. Exciting opportunities are 
now arising for the design of small synthetic molecules that bind to PRRs and influence downstream signal-
ing pathways. Such molecules can be useful tools to modulate immune responses, for example, as adjuvants 
to stimulate adaptive immune responses to a vaccine, or as therapeutic agents to dampen aberrant immune 
responses, such as inflammation. The design of agonists or antagonists of PRRs can now benefit from a surge 
in knowledge of the 3D structures of PRRs, many in complexes with their natural ligands. This review article 
describes recent progress in structural studies of PRRs (TLRs, NLRs, CTLs, and RLRs), which is required for 
an understanding of how they specifically recognize structurally diverse “foreign” PAMPs amongst a back-
ground of other “self” molecules, sometimes closely related in structure, that are present in the human body.
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1  Introduction to pattern recognition receptors
The immune system has evolved to protect organisms as diverse as plants, flies, and animals against infec-
tion by invading microorganisms. A critical first step in achieving this protection is to quickly recognize when 
infectious agents are present; the immune system must distinguish what is foreign (or “non-self”) from what 
is normally present in the body (i.e., “self”). It is the main function of the innate immune system to provide 
this rapid surveillance, using germ-line encoded proteins called pattern recognition receptors (PRRs) [1–4]. 
PRRs function by recognizing “danger signals” and then initiating an appropriate innate immune response. 
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Danger signals can be derived from both foreign pathogens as well as endogenous sources, such as lysed cells. 
The PRRs comprise four main families of proteins, some membrane-bound and others soluble cytoplasmic 
proteins that recognize molecules (or molecular patterns) associated with microbes – so-called pathogen-
associated molecular patterns (PAMPs). The activation of PRRs by binding to PAMPs initiates intra-cellular 
signaling cascades and altered patterns of gene expression that lead to a rapid first line defense against the 
invading microorganism, as well as promoting activation and maturation (more slowly – over days to weeks) 
of the adaptive immune system. The adaptive immune response is mediated mainly by B and T cells. Signals 
from the innate immune system drive the selective expansion and activation of B- and T-cell populations with 
specificity for the infectious agent, optimized through cycles of somatic mutation and selection (Fig. 1) [5]. 
The main effector mechanisms of adaptive immunity include the production of antibodies by B cells (to act 
as blocking antibodies, or as opsonins for complement- and phagocyte-mediated killing), and the killing of 
infected host cells by cytotoxic T cells. In addition, activation of adaptive immunity results in the production 
of memory B and T cells, which can provide long-term specific protection (e.g., over years to a whole lifetime) 
against subsequent infections by a pathogen bearing the same antigens [6, 7].
Adherence of microbes to the surface of cells of the innate immune system, mediated through binding 
of PAMPs to cell surface PRRs, actively promotes ingestion of the microbe and entrapment and digestion 
within phagosomes. On the other hand, soluble cytoplasmic PRRs act as sensors for intracellular pathogens. 
Through PAMP–PRR interactions, innate immune cells are activated and respond by producing inflammatory 
cytokines and chemokines that trigger responses from other cell types. Furthermore, activation of the innate 
immune system leads to deployment of a range of killing factors to attack invading pathogens. These include 
bactericidal enzymes, toxic chemicals such as reactive oxygen and nitrogen species, and antimicrobial pep-
tides (e.g., defensins). The detection of certain PAMPs may also activate the complement system, a cascade of 
triggered enzyme reactions that can lead to tagging (or opsonization) of the microbe surface with the comple-
ment protein C3b, which marks it out for destruction by other components of the immune system. Finally, 
PRR–PAMP interactions stimulate cells of the adaptive immune system, including antigen-presenting cells 
Fig. 1 The innate immune system operates largely in peripheral tissues, where it recognizes foreign pathogens. Upon binding 
of PAMPs to PRRs, the innate immune system is activated and provides a first line of defence against the invader. Subsequently, 
the adaptive immune system is activated, and with help from the innate immune system, pathogen-specific antibodies and 
killer T cells are produced (adapted from [11]).
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(APCs), such as dendritic cells (DCs) and B and T cells. DCs reside in a quiescent state in peripheral tissues, 
where they continuously sample their environment by phagocytosis and pinocytosis. DCs are equipped with 
a suite of PRRs for binding to PAMPs, thereby facilitating rapid up-take of pathogens by phagocytosis. Inside 
APCs, foreign proteins are digested into peptide fragments, which include some that act as T-cell epitopes. 
A dramatic increase in the expression of surface MHC-I and -II is elicited by PAMP–PRR binding. This leads 
to enhanced surface presentation of T-cell peptide epitopes in complexes with the membrane-bound MHC 
molecules, ready for recognition by T-cell receptors.
Immature DCs are relatively non-motile, but after activation they become highly motile and migrate 
through the lymphatic system, carrying pathogen-derived antigens to secondary lymphoid tissues, such as 
the lymph nodes. Circulating naïve B and T lymphocytes also halt in the lymph nodes, where they scan APCs 
and intact antigens draining through in interstitial fluids from peripheral tissues. Intact antigens can be rec-
ognized by B-cell receptors (BCRs) on the surface of B cells. Viruses and bacteria typically display a repetitive 
and closely spaced array of epitopes across their surface. Such an arrangement of epitopes is specifically rec-
ognized as foreign by B cells [8]. This occurs through cross-linking of multiple BCRs by multivalent binding to 
surface arrays of antigens, which generates a powerful activation signal, and initiates the process of B-cell acti-
vation and maturation [9]. The activated B and T cells then interact within the lymph nodes in a process that 
leads to the production of antibody-secreting B cells and cytotoxic T cells optimized to recognize and remove 
foreign pathogens. The activated B and T cells also harbor PRRs, and are further stimulated by repeated inter-
action with PAMPs during the course of the adaptive immune response [10]. PAMP–PRR interactions thus play 
a key role in immune responses to invading pathogens, from its beginnings through the later stages of matura-
tion of the adaptive immune response (Fig. 1). For this reason, both natural and synthetic ligands of PRRs are 
now attracting great interest as immune modulators in the fields of vaccinology and immunotherapy [6, 11–13].
PRRs can be divided into four main families, based upon their structural features as well as the type of 
PAMP they recognize [14]. These include the Toll-like receptors (TLRs), the C-type lectin receptors (CLRs), 
NOD-like receptors (NLRs), and RIG-like helicase receptors (RLRs). A review of newly described PRRs 
appeared recently [15].
1.1  Toll-like receptors (TLRs)
One of the major families of PRRs are the TLRs, so named because of their homology with the Toll receptor, 
first discovered in the 1980s in the fruit fly Drosophila [16, 17]. The Toll receptor plays a role in the development 
of the dorsoventral body axis in Drosophila, acting as a cell-surface receptor for the cytokine ligand Spätzle 
[18]. Later it was discovered that Toll and related receptors also function in the innate immune response to 
fungal and bacterial infection in the fruit fly, stimulating the release of defensins and related antimicrobial 
peptides [19]. As genome sequencing advanced, about 10 directly homologous receptors were later discov-
ered in vertebrates, and these became known as the Toll-like receptors (for a recent historical account, see 
[20]). The ligands for most of these receptors are now known. The ligands display remarkable structural 
diversity, and include bacterial peptidoglycan (PGN), lipoproteins, lipopolysaccharide (LPS), mycobacterial 
lipoarabinomannan, yeast zymosan, and bacterial flagellin, as well as pathogen-derived nucleic acids [21].
To date, 10 TLRs have been reported in humans and 13 in mice. The TLRs are type I integral membrane 
glycoproteins that are located either in the outer cell membrane (TLR1, 2, 4, 5, 6, 10, 11, 12), or in endosomal 
membranes with their ectodomains facing the internal space of the endosome (TLR3, 7, 8, 9, 13) (Fig. 2). They 
contain an N-terminal extracellular domain (ECD) of between 550 and 800 residues, a single helical transmem-
brane domain of ≈20 residues, and a C-terminal intracellular signaling domain of ≈180 residues, called a “Toll 
IL-1 receptor” (TIR) signaling domain, because it shares homology with the signaling domains of IL-1R family 
members. The crystal structure of the TIR domain of TLR1/2 was published in 2000 [22]. Some TLRs act as het-
erodimers, including TLR1/2 and TLR2/6, which respond to different bacterial lipoproteins. All TLRs share a 
common basic 3D architecture, with multiple leucine-rich repeats (LRRs) arranged in a horseshoe- or crescent-
shaped structure that together comprises the N-terminal ectodomain responsible for PAMP-binding. A single 
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transmembrane segment links the ectodomain to the C-terminal domain, which interacts with adapter proteins 
in the cytoplasm, an event that culminates in activation of transcription factors, such as NFκB and members of 
the interferon-regulated factors (IRFs) family, which in turn leads to altered patterns of gene expression [23, 24].
1.2  C-type lectin receptors (CLRs)
The C-type lectin receptor (CLR) superfamily is a large group of proteins that are widely distributed in nature 
[25, 26]. C-type lectins are Ca2+-dependent carbohydrate-binding proteins that contain one or more C-type 
lectin (or lectin-like) domains (CTLDs), with related folds dictated by a common sequence motif. When such 
domains bind to carbohydrates, they are called carbohydrate recognition domains (CRDs). A CRD is present in 
all Ca2+-dependent lectins, but not in other (Ca2+-independent) types of animal lectins. A recent review grouped 
the CTLDs into 17 different classes [25]. Of special interest here are the class-II asialoglycoproteins on APCs that 
function as PRRs in the innate immune system. These type-II membrane receptors contain a short cytoplasmic 
domain, a single transmembrane segment, and an ectodomain comprising a stalk region involved in oligomer-
ization, which is linked to one or more CRDs. Professional APCs, such as macrophages, DCs, and B cells, are 
equipped with receptors that collectively allow them to recognize, capture, and internalize foreign antigens. 
Besides the B-cell receptor found only on B cells, other APCs use germ-line encoded membrane proteins for 
detecting foreign antigens that include Fc receptors, complement receptors, the TLRs, and the CLRs. TLRs are 
not able to promote internalization of antigens, whereas this is an important function of CLRs. Representatives 
of the class-II CLRs are ICAM-3, DC-SIGN, MGL, LANGERIN, MINCLE, DECTIN-2, BDCA-2, DCIR, and DCAR. 
The class-V CLRs are also known as type-II natural killer (NK) cell receptors, and include DCAL-1, DCAL-2, and 
dectin-I. Finally, the class-VI CLRs include the mannose receptor (MR) and lymphocyte antigen 75 (DEC-205).
CLRs are important in immune recognition of glycoproteins and cell wall glycolipids derived from viruses 
and microbes, and mediate pathogen uptake and phagocytosis [27, 28]. However, the biological functions of 
Fig. 2 Ten TLRs have been identified in humans, and are located either on the outer cell membrane or the membrane of 
endosomes within the cytoplasm of immune cells. When PAMPs bind to the ectodomain of the TLR, signals are transmitted 
into the cell via intracellular (TIR) domains [22], which bind and activate transcription factors [NFkB and/or members of the 
interferon-regulated factors (IRFs)]. The transcription factors promote expression of numerous genes that alter the activation 
state of the cell, as well as for inflammatory cytokines and chemokines that are exported and signal to other cells (see Fig. 1).
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CTLs are more complex than just facilitating antigen uptake by DCs. Many of the carbohydrates recognized 
by CLRs are not unique to pathogens but can also be found on many self-glycoproteins [27]. Hence, self- and 
non-self-structures may be recognized by CLRs, which is a reflection of the multiple and complex functions 
these receptors, as a whole, have in the maintenance of immune homeostasis [29–32]. Ligand binding to 
these receptors can also activate signaling pathways that modulate TLR signaling, activate innate immune 
responses, and influence adaptive immune responses [30, 31].
The C-type (calcium-dependent) lectin (CTL) family of proteins is found on the surface of cells of the innate 
immune system, including macrophages and DCs [28, 29, 33]. The membrane-bound CTLs bind oligosaccha-
rides, in particular, containing d-mannose and l-fucose residues, using highly conserved carbohydrate recog-
nition domains (CRDs). Many CTLs on APCs contain only a single CRD, well-known examples being DC-SIGN, 
DCIR, MGL, and Langerin. Others, such as DEC-205 and the mannose receptor (MR), possess 8–10 CRDs within 
their extracellular regions [25, 34–36]. According to their carbohydrate specificities, CLRs tend to be classi-
fied as either mannose/fucose- or galactose-recognizing lectins. Some CLRs share carbohydrate ligands. For 
example, the trisaccharide Lewisx can serve as a ligand for DC-SIGN and the MR. However, ligand promiscuity 
is also seen, for example, with DC-SIGN, which is able to recognize efficiently different Lewis-type epitopes as 
well as high-mannose glycans. CLRs have now become attractive targets for ligand design, for use in targeting 
antigens to DCs, and for modulating antigen-specific immune responses [28, 29, 33].
1.3  NOD-like receptors (NLRs)
The nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) function as intracellular sur-
veillance sensors to detect microbial products and danger signals inside cells [37–41]. Some NLRs are also 
involved in inflammatory responses and apoptosis, and thus as a whole the NLRs mediate diverse biologi-
cal functions in innate immunity [39, 42–46]. NLR family members are found in plants, invertebrates, and 
mammals, although NLR structure and function has been most thoroughly studied in mice and humans [47]. 
The NLRs are subdivided into five subfamilies, into which the 22 human NLRs are grouped as follows; NLRA 
(CIITA), NLRB (NAIP), NLRC (NOD1, NOD2, NLRC3, NLRC4, NLRC5, NLRP and NRLX), NLRP (NLRP1-14), and 
NLRX (NLRX1) (Fig. 3) [48]. Some NLRs activate a proinflammatory response (such as NOD1 and NOD2), others 
form a large multiprotein complex called an inflammasome [47, 49] resulting in cleavage of procaspase-1 and 
formation of activated caspase I (NLRP1, 3, 6, 7, and 12, and NLRC4), others provide immunoregulatory func-
tions (NLRC3 and 5, CIITA, and NLRP10), while others have roles in development (NLRP2, 5, 7, and 14) [48, 50].
The NLRs are soluble cytoplasmic proteins, important for sensing infectious agents that have gained access 
to the interior of the cell [48, 50–52]. There are 22 NLRs in humans and 34 in mice [53], which exhibit character-
istic multidomain structures, typically consisting of a central nucleotide binding domain (NBD) that contains a 
Fig. 3 Domain architecture of representative human NLRs [47, 52]. Abbreviations: LRRs, leucine-rich repeats for ligand sensing; 
NACHT, a nucleotide binding and oligomerization domain; PYD, pyrin effector domain; BIR, baculovirus inhibitor repeat effector 
domain; CARD, caspase activation and recruitment effector domain; NBD, nucleotide binding domain; FIIND, function to find domain.
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NACHT and other subdomains, an N-terminal effector binding domain most commonly a CARD (caspase activa-
tion and recruitment domain), a BIR (baculovirus inhibitor repeat), or a pyrin (PYD) domain, and a C-terminal 
putative ligand-binding domain comprising multiple leucine-rich repeats (LRRs) (Fig. 3) [39, 40, 48]. The effec-
tor domains bind downstream signaling molecules, ultimately leading to activation of protein kinases, tran-
scription factors, proteases, and other components of host defense and inflammatory responses [38, 50].
Some of the PAMPs detected by NLRs have been identified. For example, NOD1 and NOD2 sense frag-
ments of PGN [37]. Macrophages contain intracellular hydrolases that digest bacterial PGN. NOD1 detects a 
minimal PGN fragment containing γ-d-glutamyl-meso-diaminopimelic acid that is found almost exclusively 
in Gram-negative bacterial PGN [54]. On the other hand, NOD2 detects muramyl-dipeptide (MurNAc-l-Ala-d-
isoGln), which is a common motif in PGN in almost all bacteria [55, 56]. NLRP3 and NAIP respond to a remark-
ably diverse set of PAMPs [39], whereas NLRC4 senses bacterial flagellin [57, 58], and NLRX1 binds to RNA [59].
1.4  RIG-like helicase receptors (RLRs)
How does a cell distinguish viral nucleic acid (RNA) in the cytoplasm from its own? An important clue came 
by recognizing that viral RNA is structurally different in ways that mark it out as foreign to the cell. Thus, 
dsRNA is virtually absent in mammalian cells, whereas some viruses generate dsRNA as a byproduct of viral 
RNA replication, containing transiently an uncapped 5′-triphosphate group. Cellular primary transcripts 
also contain 5′-triphosphate, however, many self-RNAs undergo processing steps that remove or mask the 
5-triphosphate moiety. For example, mRNAs are capped by methylation at the 5′-terminus, tRNAs undergo 
cleavage of 5′-PPP groups before they reach the cytoplasm, and ribosomal RNAs form complexes with riboso-
mal proteins. The retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) are constitutively expressed in 
the cytoplasm of most cells, including DCs and macrophages as well as non-immune cells, where they act as 
cytosolic sensors of viral RNA [60, 61].
RLRs provide a first line of defense against infection by RNA viruses, including influenza, rift valley, 
measles, vesicular stomatitis, and hepatitis C viruses [61]. There are three members of the RLR family: RIG-I 
(also known as DDX58), “melanoma differentiation associated factor gene 5″ (MDA5), and “laboratory of 
genetics and physiology 2” (LGP2). Recognition of the 5′-PPP terminus unique to viral RNA, either in a dsRNA 
or a hairpin-looped structure, a so-called pan-handle-like RNA, is an important function of RIG-I [62, 63]. The 
prototypical ligand of RIG-I is a short RNA with a blunt-ended base-paired, and uncapped 5′-triphosphate 
terminus. Until very recently, much less was known about the nature of RNAs recognized by MDA5. MDA5 
generally responds to long dsRNA molecules. However, RIG-I and MDA5 may also be activated by self-RNAs 
that are cleaved by RNaseL. The function of the third RLR, called LGP2, has been less well studied, but seems 
to participate in RIG-I and MDA5-dependent antiviral responses [60, 61].
RIG-1 and MDA-5 possess a conserved central helicase-like domain, linked to two N-terminal caspase 
activation and recruitment domains (CARDs), and a Zn2+-containing C-terminal domain (CTD) (Fig. 4). LGP2 
Fig. 4 Domain structures of RLRs. RIG-1 and MDA-5 have the same domain architecture. Abbreviations: CARD, caspase activa-
tion and recruitment effector domain; CTD, C-terminal regulatory domain; HEL2i, helicase insertion domain; HEL1/2 helicase 1/
helicase 2; P, pincer domain.
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has similar domain architecture, although it contains no CARD domains. The ligands that function as RLR 
activators are typically virus-specific RNA structures, including 5′-triphosphate linked to single-stranded or 
blunt-ended, double-stranded RNA, as well as poly I:C (a synthetic analog of viral dsRNA). Upon binding 
to such PAMPs, RIG-1 initiates a signaling cascade that induces innate immune defenses and inflammatory 
cytokines to establish an antiviral state [64]. However, knowledge of the complex regulatory mechanisms that 
control signaling through these PRRs is incomplete. Aberrant RIG-1 signalling can lead to apoptosis, altered 
cell differentiation, inflammation, autoimmune disease, and cancer. Apart from RLRs, several other members 
of the helicase superfamily have been proposed to participate in intracellular sensing of pathogen-derived 
nucleic acids, including DDX1/3/21/36, DHX9/36, and STING [60].
2  Structures of toll-like receptors
2.1  Overview
Several reviews on TLR structural biology have been published recently [16, 65, 66]. TLR ECDs are con-
structed of tandem copies of a structural motif known as the leucine-rich repeat (LRR). LRRs are found 
in several thousand proteins involved in a wide variety of physiological functions in all kingdoms of life, 
including immune responses, signal transduction, cell-cycle regulation and enzyme regulation (for reviews, 
see [67–69]). These proteins typically contain 2–40 tandem LRR modules, which form curved horseshoe- or 
solenoid-like structures that seem to be well suited for protein–protein and protein–ligand interactions. 
The 10 human TLRs contain 19–25 LRR modules. Each LRR typically contains a ≈20–30 residue consensus 
sequence (Fig. 5a), which includes the characteristic motif LxxLxLxxNxL (x  =  any amino acid), although 
other hydrophobic residues can substitute for Leu, and other amino acids capable of donating hydrogen 
bonds (T, S, C) can substitute the Asn residues [67, 70]. Each LRR module adopts a folded structure com-
prising one β-strand that includes the entire consensus motif, followed by a bridging loop that often con-
tains helical and/or turn-like elements that fold back over the β-strand, thereby burying the hydrophobic L 
Fig. 5 (a) Characteristic LRR motif, and structure of one LRR module. Orange, β-strand; green, bridging loop. (b) The typical 
horseshoe, or solenoid-like structure of a TLR ectodomain. (c) The disulfide-rich capping modules at the N- (LRR-NT) and 
C-terminus (LRR-CT).
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residues (Fig. 5a). The bridging loop is linked to the β-strand of the next LRR, which is aligned so that the 
β-strands form a regular hydrogen-bonded parallel β-sheet. This arrangement can now be repeated by addi-
tion of more LRRs, which generate a horseshoe- or solenoid-like tertiary structure, as shown in Fig. 5b. The 
resulting curved parallel β-sheet forms the inner concave face of the horseshoe, whereas the residues in the 
adjacent bridging (often helical) loops form the outer convex surface of the horseshoe. The ECDs of most 
TLRs are glycoproteins, in which surface-exposed Asn residues carry N-linked glycosylation. The side-by-
side nestling together of LRRs in these proteins ensures that the hydrophobic residues are buried internally. 
The situation is different for the N- and C-terminal LRR modules, where one side of the hydrophobic core 
will not be covered by another LRR module. Instead, capping modules are added to the termini (LRR-NT and 
LRR-CT) (Fig. 5c). The capping modules do not show the same conserved sequence and structural motifs. 
They typically comprise smaller disulfide-bonded folds that pack across the hydrophobic core and leave 
polar surface residues exposed to the solvent.
The LRR horseshoe geometries have been characterized by three parameters – the radius of the horseshoe 
arc (“radii” R), the mean rotation angle about the central axis relating one β-strand to the next (“twist”), and 
the tilt angle of the parallel β-strand direction per turn (“tilt”) [68]. The observed values of R, for example, 
range from 1.5 to 4.7 nm, so the arc of LRR family members can possess quite different degrees of curvature. 
LRR family proteins have been subdivided into seven subfamilies based on sequence and structural compari-
sons. They are “RI-like”, “CC”, “bacterial”, “SDS-22-like”, “plant-specific”, “typical”, and “TpLRR” [69, 71]. 
The “typical” subfamily includes all the TLRs. However, phylogenetic analyses suggested that two distinct 
subclasses of “typical” TLRs exist, the single- and three-domain TLR subclasses, which diverged early in 
evolution [66, 72].
The ECDs of TLR1, 2, 4, and 6 belong to the three-domain subclass [66]. These TLRs have two structural 
transitions in the concave β-sheet face of the ECD, thereby creating N-terminal, central, and C-terminal sub-
domains (Fig. 6). The central domains have radii, twist, and tilt angles that deviate markedly from the stand-
ard values of the “typical” single-domain subfamily members. This appears to be caused by several unusual 
features, including LRRs in the central domain that lack the characteristic Asn residue within the consen-
sus motif. This Asn side chain usually interacts in a ladder of hydrogen bonds with surrounding backbone 
carbonyl oxygens, thereby stabilizing the horseshoe structure. In addition, the LRR modules of the central 
domains vary in size from 20 to 33 residues, whereas in the N- and C-terminal domains, the LRR modules are 
mostly 24 residues. The LRR modules in the central region have bulkier α-helical segments on the exposed 
convex face, which take up more space, leading in turn to greater curvature and a smaller arc radius in the 
central domain. These structural features are also important for the biological function of these TLRs because 
the central domains play an important role in binding ligands or co-receptors. Although no crystal structure 
is available, TLR10 also appears to contain broken Asn ladders and greater variation in module length in the 
central part of the ECD, and so is also likely to belong to the three-domain subfamily.
Fig. 6 Single-domain (left) and three-domain (red, green, and blue, right) TLR subclasses. The characteristic Asn residues 
(show in orange/red/blue ball-and-stick) in each repeat motif, and the ladder of hydrogen-bonds (in light blue) they form are 
shown.
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In contrast, TLR3, 5, 7, 8, and 9 belong to the single-domain subfamily. Their LRR modules have con-
served Asn residues within the consensus motif and relatively uniform module lengths. Functional and phy-
logenetic analyses provide support for these correlations, which in the cases of TLR3 and 8 is also supported 
by structural (crystallographic) information. TLR7, TLR8, and TLR9 are predicted by sequence comparisons to 
contain “island regions”, comprising substantial domains that loop out of the external surface of the horse-
shoe architecture [73].
Strong evidence exists that active TLRs function as homo- or hetero-dimers, and/or as part of supramo-
lecular complexes with other membrane-associated proteins. For example, TLR2 signals as a heterodimer 
in a complex with either TLR1 or TLR6. Crystal structures of the ECDs of the TLR1/2 and TLR2/6 heterodi-
mers show how specific lipopeptides are recognized by these receptors (vide supra) [74, 75]. In the case of 
the TLR2/6 heterodimer, a plasma membrane protein (CD36) of the class B scavenger receptor family, also 
participates in signaling [76]. Although human TLR3 ECD is found as a monomer in the crystal structure [77, 
78], it binds its target double-stranded (ds) RNA as a dimer [79, 80]. Moreover, clustering of multiple TLR3 
homodimers may occur at the cell surface through binding to long dsRNAs [79, 81]. FRET studies suggest that 
TLR9 exists as preformed inactive dimers in the cell membrane that change conformation upon binding to 
DNA rich in CpG dinucleotides. Ligand binding then results in allosteric changes in the cytoplasmic sign-
aling domains, which lead to receptor activation and signaling [82]. TLR5, the only protein-binding TLR, 
responds to a monomeric form of bacterial flagellin that, in oligomeric form, constitutes the flagellar tail 
responsible for swimming locomotion in β- and γ-proteobacteria. A crystal structure of an engineered TLR5-
flagellin complex revealed a 2:2 subunit stoichiometry, with two TLR5 ECDs in a tail-to-tail organization [83]. 
Finally, TLR4 forms a stable 1:1 heterodimer with MD-2, and the resulting TLR4-MD-2 complex is responsible 
for recognition of lipopolysaccharide (LPS) from Gram-negative bacteria. Cells transfected with TLR4 are not 
responsive to LPS, but are when complemented with MD-2 [84]. Moreover, another membrane-associated 
protein, CD14, is required for full ligand recognition and signaling through TLR4. TLR4 may be organized 
into a supramolecular complex through interactions with MD-2 and CD14 (and perhaps other components) 
at the cell surface [76, 85, 86].
TLRs interact with an unusually diverse variety of ligands. These ligands range from naturally occurring 
highly nonpolar lipids, such as LPS and lipopeptides, through to polar macromolecules such as DNA, RNA, 
and the protein flagellin. It is also important to remember that the same TLRs from different species may 
exhibit differences in the way they recognize and respond to the same or closely related ligands [87].
2.2  Structures of TLR1/2 and 2/6
Various earlier reports suggested that TLR2 is able to recognize a diverse array of microbial structures, 
although most are glycolipids (such as lipoteichoic acid (LTA), lipoarabinomannan, and LPS), lipopeptides/
lipoproteins, or glycosyl-phosphatidyl-inositol (GPI)-anchored structures [88]. However, some purported 
TLR2 ligands lack clear structural relationships to lipidic molecules, such as fragments of PGN and the poly-
saccharide zymosan isolated from yeast. This led to the suggestion that TLR2 is a rather “promiscuous recep-
tor” [89]. This view has now changed, with the realization that some of the potential ligands tested in earlier 
studies were isolated from biological sources and were likely to contain trace amounts of bacterial lipopro-
teins/lipopeptides [88]. The extent of the analytical problem can be understood by noting that some PAMPs 
may activate PRRs at picomolar (pM) concentrations, whereas some cellular studies of TLR2 activation were 
performed with “purified” ligands in the micromolar range. Ideally, ligands of synthetic origin should be 
tested in receptor activation assays, although their structural and stereochemical complexity often makes 
this difficult. Very recently, structural studies have reinforced the view that only lipopeptides/lipoproteins 
containing Pam2Cys or Pam3Cys [or those with related acyl chains (Fig. 7)] represent specific ligands of TLR2, 
recognized by heterodimers of TLR1/2 or TLR2/6. In contrast, the lipid anchor in LTA, the GPI-anchored lipids 
in lipoarabinomannan, as well as related glycolipids frequently found in membrane of higher organisms do 
not activate TLR2 at physiologically relevant concentrations [88].
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Crystal structures have revealed that the TLR1/2 heterodimer binds to lipoproteins with a triacylated 
N-terminus (such as Pam3Cys), while the TLR2/6 heterodimer binds to lipoproteins with a diacylated N-ter-
minus (such as Pam2Cys). All bacterial lipoproteins contain a glycerol moiety linked via a thioether to the 
side chain of an N-terminal Cys residue (S-[2,3-bis(acyloxy)-(2R)-propyl]-(R)-cysteinyl), and acylated with two 
long-chain fatty acids. Lipoproteins anchored in the membrane of Gram-positive bacteria generally have a 
free N-terminus. In Gram-negative bacteria, however, lipoproteins contain three lipid chains (Fig. 7); a third 
acyl chain is attached directly to the N-terminus of the peptide/protein. During the biosynthesis of lipopro-
teins [90]), an inner membrane enzyme (Lgt) transfers the diacylglycerol moiety from membrane phospholip-
ids to the N-terminal cysteine residue of the pre-lipoprotein. The acyl chains are typically palmitoyl groups, 
although other chain lengths and levels of unsaturation are found in different bacteria [90]. Gram-positive 
bacteria generally lack the lipoprotein N-acyltransferase (Lnt) required to attach the third amide-linked acyl 
chain to the N-terminus [91]. Mycobacteria are a special case, since they are high-GC Gram-positive bacteria, 
albeit with a special outer layer of unique lipid components called mycolic acids covalently linked to the 
PGN. They contain the Lnt enzyme and so are able to produce triacylated lipoproteins carrying mycobacteria-
specific fatty acids [92]. Mycoplasma, on the other hand, are low-GC Gram-positive bacteria without cell walls 
(no PGN or LPS), with a cytoplasmic membrane that is stabilized by the presence of sterols and lipoglycan 
(long-chain heteropolysaccharides covalently linked to membrane lipids [93, 94]). Lipoproteins in the cell 
membrane of Mycoplasma are of the Pam2Cys variety [95, 96].
The residues immediately downstream of the N-terminal Cys in bacterial lipoproteins are variable in 
sequence, but the first is typically Gly or has a small polar side chain. The following residues appear not 
to exert a strong influence on signaling by the TLR1/2 heterodimer (vide supra) [97–99]. Structure–activity 
studies with triacylated lipopeptides have revealed that the immune modulatory activity is strongly depend-
ent on the fatty acid chain length and the correct absolute configuration of the natural 2R-dihydroxypropyl-
R-cysteine. Also, replacement of the sulfur by CH2 reduces biological activity significantly [99].
The Gram-positive bacterial membrane is surrounded by a thick cell wall of PGN, so their lipoproteins 
are typically embedded under this barrier and are not accessible to cellular receptors. Furthermore, Gram-
negative bacteria have an asymmetric outer membrane (OM) with a layer of LPS molecules forming the outer 
Fig. 7 Structures of lipoproteins Pam2Cys and Pam3Cys, and the lipid derivatives PE-DTPA and LTA.
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leaflet and exposed on the outer cell surface; lipoproteins are anchored in the inner leaflet of phospholipids 
and face the periplasm. As a result, lipoproteins in both types of bacteria are not immediately accessible for 
binding to PRRs. This accessibility problem is likely solved during the initial stages of the innate immune 
response, when bacterial cells are engulfed by macrophages and undergo phagocytosis with subsequent deg-
radation of the cell wall. During this process, bacterial lipoproteins are released and can interact with TLRs 
[90].
2.2.1  The human TLR1/2 heterodimer
Lipopeptide ligand is required to induce formation of heterodimers of TLR1 and TLR2. The full-length recep-
tors on the plasma cell membrane form weakly associated homo- and heterotypic multimers without bound 
ligand. However, lipopeptide binding induces rearrangement to the more stable heterodimer, which then 
initiates signaling [100, 101].
To facilitate production and crystallization of human TLR1 and TLR2, a large number of recombinant 
hybrid fusion proteins were designed and screened to identify constructs suitable for crystallization [74, 102]. 
This approach led to the identification of two fusion proteins, called hT1V8 and hT2V9, in which 105 resi-
dues from the C-terminus of human TLR1 and 82 residues from the C-terminus of human TLR2, respectively, 
were replaced with fragments of hagfish variable lymphocyte receptor (VLR). These fusion proteins formed a 
stable and crystallizable heterodimeric complex with the lipopeptide Pam3CysSK4.
The structure of the TLR1/2-Pam3CSK4 complex confirmed the horseshoe-like geometry of each TLR chain 
[74]. Viewed from the side, the overall shape of the complex resembles the letter “m”, with the two C-termi-
nal VLR domains adjacent in the middle, but not in direct contact with each other nor with other TLR resi-
dues (Fig. 8). The ECDs of TLR1 and TLR2 contain the distinctive three-subdomain organization (vide infra). 
The N-terminal domain contains the LRR-NT capping motif and LRRs1-4, each with typical 24-residue LRR 
repeats. The hydrogen-bonding Asn ladder and a spine formed by consecutive Phe residues are conserved in 
this region. In contrast, the central and C-terminal subdomains have LRR modules with atypical sequences, 
and their β-sheet conformations deviate from those seen in standard LRRs. The central subdomain also lacks 
the Asn ladder and the Phe spline.
The TLR1/2 chains make contact with each other through LRRs in the central domain, near the center of 
the “m”, where the binding site for the lipopeptide is also located. From one orientation, the two ester-linked 
lipid chains project forwards and interact with a pocket on TLR2, whereas the amide-linked lipid chain pro-
jects backwards and inserts into a narrow channel in TLR1 (Fig. 9a and b). The protein–protein interaction 
between the two TLR chains extends over 850 Å2, with a near circular interface and the bound ligand located 
near the center.
Fig. 8 Structure of the TLR1/2-Pam3CSK4 complex; TLR2 (blue), TLR1 (green), lipid (red). View from the side with membrane 
below (left), and from the top of the complex looking down onto the membrane (not indicated) (right).
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The TLR chains in the heterodimer make contact with each other and the lipopeptide ligand through the 
sides of each horseshoe. An opening is created in the side of TLR2 by the presence of a large helical loop that 
projects up and outwards from LRR module 11, thereby allowing the two ester-linked lipid chains to insert into 
a deeply buried cavity that extends into the region between the β-sheet base and the bridging helical loops 
of LRR modules 10–12 (Fig. 9c). The two lipid chains occupy over 90 % of the total solvent accessible volume 
of the pocket. The lack of an Asn ladder and spine of phenylalanine residues within the central LRRs in TLR2 
helps to account for the formation of this deep binding pocket. In a similar fashion, an opening between two 
LRR repeats in the central domain of TLR1 allows the amide-linked lipid chain to insert into a hydrophobic 
pocket between LRR modules 11 and 12. This pocket is only one-quarter the volume of that in TLR2, but is fully 
occupied by the amide-linked palmitoyl chain. All three bound lipid chains adopt mostly extended conforma-
tions, but gauche backbone conformations also exist at some points along the lipid backbone.
The conserved cysteinyl-glycerol moiety of the ligand exits the TLR1/2 complex through an opening lying 
between the two TLR chains. A series of hydrogen-bonding interactions between backbone carbonyl oxygen 
and nitrogen atoms of the TLRs and the ligand, as well as complementary surface contacts, appear to stabilize 
the complex (Fig. 9d). Small amino acids (Gly/Ser) are preferred in the second position (after Cys) in bacterial 
lipoproteins. Consistent with this, the second amino acid (Ser) of the synthetic ligand Pam3CSK4 is located in 
the narrow neck region of the binding pocket, where space for a side chain is limited. The side chains of the 
four Lys residues make only limited interactions with TLR1 or TLR2, consistent with the low sequence conser-
vation found at these positions in bacterial lipoproteins.
2.2.2  The mouse TLR2 monomer
Crystal structures have also been reported for a mouse TLR2-hagfish VLR fusion protein, in complexes with 
Pam3CSK4 and Pam2CSK4 [74]. The protein is a monomer in solution and when crystallized with each lipopep-
tide ligand. The structures of the mouse and human TLR2 ECDs are highly homologous (1.1 Å rmsd over the 
Fig. 9 The TLR1/2_Pam3CSK4 complex. (a) The bound ligand situated near the center of the TLR1/2 protein–protein interface. 
(b) Slice through the complex. The two ester-linked lipids project into a binding pocket in TLR2 (blue) and the amide-linked 
lipid into one in TLR1 (green). (c) the lipid-binding cavity (with mesh) and entrance lies near LRR modules 10-12 (light blue). 
(d) Hydrogen-bonding interactions (pink dotted) with the ligand head-group.
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backbone atoms), as expected from their high sequence identity (68 %). The two different lipopeptides bind 
to mouse TLR2 in an almost identical fashion, with the two ester-linked lipid chains inserted into the lipid-
binding pocket. The amide-linked peptide chain, however, and the peptide portion of both ligands remain 
solvent exposed and are not visible in the electron density map. An interesting difference is found in the 
shape of the lipid-binding pockets of TLR2 between the two species, caused by sequence differences in resi-
dues lining the binding pocket. The ligand-binding pocket is slightly shorter in the mouse TLR2 compared to 
human TLR2. As a result, mTLR2 binds shorter lauroyl chains (C12) more efficiently than hTLR2 [103]. This is 
reflected in the ability of lauroyl3CSK4 to activate mouse but not human TLR2 [104]. Deletion or more marked 
truncation of the two ester-bound lipids abolishes TLR2 activation [103].
Additional structures have been reported of mouse TLR2-VLR fusion proteins bound to bacterial 
lipoteichoic acid from Streptococcus pneumonia (pnLTA), and to PE-DTPA, a synthetic derivative of phos-
phatidylethanolamine linked to a metal-coordinating DTPA group (1,2-dimyristoyl-sn-glycero-3-phospho-eth-
anolamine-N-diethylenetriaminepentaacetic acid) (Fig. 7) [75]. Both pnLTA and PE-DTPA bind to TLR2, but 
have little or no ability to activate the receptor. LTA typically contains a long chain of ribitol or propanolamine 
repeating units that are anchored in the cell membrane by linkage to a diacylglycerol head group. pnLTA 
binds to TLR2, but does not induce heterodimerization and signalling of TLR1/2 or TLR2/6, consistent with the 
substantially weaker proinflammatory activity of pnLTA compared to bacterial lipoproteins.
In the monomeric TLR2-pnLTA complex, the overall horseshoe-like shape of the ECD and structure of 
the lipid-binding pocket is unchanged (Fig. 10a and b). However, the LRR10 and LRR11 surface loops and the 
position of the ligand head group are significantly altered from those in the TLR1/2-Pam3CSK4 and TLR2/6-
Pam2CSK4 (discussed below) complexes. This is perhaps not surprising, given that the lipid chains are linked 
to a peptide chain in Pam2/3CSK4 and to a saccharide chain in pnLTA. In the TLR2-pnLTA structure, the posi-
tion of the sugar head group of LTA is translated by ≈5.2 Å and rotated by ≈110° toward the lateral surface of 
the horseshoe-like structure (Fig. 10c).
PE-DTPA (Fig. 7) is a synthetic lipid closely related in structure to the abundant phospholipids in cel-
lular membranes. PE-DTPA can bind to TLR2 but cannot induce formation of TLR1/2 or TLR2/6 heterodimers. 
As in other structures containing lipid-bound TLR2, the acyl chains of PE-DTPA are inserted into the same 
Fig. 10 Structures of the mTLR2-LTA and mTLR2-PE-DTPA complexes. (a) The mTLR2-LTA complex. (b) The LRR10 and 11 loops 
and position of the LTA ligand head-group are altered from those in the TLR1/2/Pam3CSK4 complex. (c) The head group of bound 
DTPA (green) resembles that in the complex with LTA rather than that seen in the TLR1/2/Pam3CSK4 complex (orange).
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lipid-binding pocket in TLR2. However, the structure of the LRR11 loops and the position of the PE-DTPA head 
group more closely resemble those seen in the TLR2-pnLTA complex (Fig. 10c). The fact that both pnLTA and 
PE-DTPA show little or no ability to activate TLR2, and adopt similarly shifted head group binding sites, sug-
gests that the head group structure plays an important role in heterodimerization and hence in TLR2 activa-
tion. Bacterial lipopeptides show the strongest TLR2 stimulatory activity [88] most likely because they induce 
stable heterodimerization of the ECDs of TLR2 with TLR1 or TLR6.
2.2.3  The mouse TLR2/6 heterodimer
To improve protein production and crystallization, C-terminal LRRs in the ECDs of mouse TLR2 and mouse 
TLR6 were replaced with equivalent regions from the hagfish VLR. Although the engineered TLR2 and TLR6 
hybrids each purify as monomeric proteins, they formed a stable heterodimeric complex when incubated 
with the synthetic lipopeptide Pam2CSK4. Binding of the lipopeptide induces the formation of a familiar “m”-
shaped heterodimer, with the N termini stretched out to opposite ends and the C-termini converged in the 
middle (Fig. 11) [75]. Heterodimerization of the ECDs in this way likely enforces juxtaposition and activa-
tion of the intracellular TIR domains. Like the TLR1/2 heterodimer, the lipopeptide-binding site in TLR2/6 is 
located on the sides of each horseshoe at the center of the “m”-shaped complex. As in the TLR1/2-lipopeptide 
complex, both ester-linked lipid chains are inserted through an opening between LRR11 and LRR12 into a 
hydrophobic pocket in TLR2 of ≈1200 Å3 formed by hydrophobic residues from LRR9-12 (Fig. 12a). The ester-
bound lipid chains adopt similar structures when bound to TLR2/6 and TLR1/2, but the Me-ends of the chains 
in the two complexes diverge slightly in different directions at the bottom of the binding pockets, most likely 
due to sequence differences between mouse and human TLR2s.
Protein–protein interactions between TLR2 and TLR6 are mediated by surface-exposed residues in 
modules LRR11-14. The LRR11 and LRR12 loops of both TLR2 and TLR6 are located at the center of the inter-
face and contribute key hydrophobic interactions. The surface area of the hydrophobic core of the TLR2/6 
interface is increased by ≈80 % compared to that in the TLR1/2 complex (Fig. 11). These hydrophobic contacts 
are surrounded by a ring of polar hydrogen-bonding and ionic interactions. It seems that the more extensive 
protein–protein interface in the TLR2/6 heterodimer might help to compensate for the lack of an amide-linked 
lipid chain, which should help stabilize the TLR1/2-ligand complex.
The structures of the glycerol moiety and the peptide backbones of the ligands in the hTLR1/2-Pam3CSK4 
and muTLR2/6-Pam2CSK4 complexes can be superimposed almost exactly. However, important structural 
differences are seen in the positions of surface residues near the LRR11 loop that influence access to the 
Fig. 11 Structure of the TLR2/6 heterodimer with bound lipopeptide Pam2CSK4 (not shown). The hydrophobic core of the 
protein–protein interface is larger than in the TLR1/2 complex.
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Fig. 12 Structural comparisons of the TLR2/6-Pam2CSK4 and TLR1/2-Pam3CSK4 complexes. (a) In both complexes, the two ester-
linked lipid chains in Pam2CSK4 are inserted into a hydrophobic pocket on TLR2. (b) Only a very restricted hydrophobic pocket is 
present in TLR6. (c) This pocket in TLR1 is larger and contains the amide-linked lipid chain in the ligand.
lipid-binding channels in TLR1 and TLR6, in particular, F317 in TLR6, which corresponds to F312 in TLR1 (Fig. 
12b and c). This region on TLR1 forms the opening of the binding site for the amide-linked lipid in Pam3CSK4. 
In addition, the bulky side chains of F343 and F365 in TLR6, buried in the middle of the pocket, shorten 
considerably the lipid-binding channel. As a result, the hydrophobic binding pocket in TLR6 is less than half 
as long as that in TLR1. These changes likely contribute significantly to the markedly reduced affinity of the 
TLR2/6 heterodimer for triacylated lipoproteins. Thus, typical amide-bound lipid chains are too long to fit 
into the short TLR6 lipid channel. This conclusion is supported by mutagenesis experiments. For example, 
an F343M and F365L double mutation of TLR6, which extend the binding pocket, allowed an almost complete 
response of the TLR2/6 heterodimer to triacylated as well as diacylated lipopeptides [75].
Other differences between the complexes include a repositioning of surface residues in TLR6, which 
allow a new hydrogen-bonding interaction with the first peptide bond of the ligand, which is not seen in 
TLR1 (Fig. 12c). On the other hand, many polar and hydrophobic contacts between the polar head group 
of the ligand and TLR2/6 are conserved, and are likely responsible for the strong stereospecific recognition 
by both receptor heterodimers of essentially the same head group in both types of lipoprotein/lipopeptide. 
Using chemically synthesized lipopeptides derived from the lipoprotein MALP2 from Mycoplasma fermen-
tans, it was shown that the R stereoisomer (S-[2,3-bis(acyloxy)-(2R)-propyl-(R)-cysteinyl-GNNDESNISFKEK]) 
exhibits much higher specific activity than the S-stereoisomer [105]. The side chains of the first two amino 
acids (CS) in the ligand also make polar interactions with TLR2/6 (Fig. 12c), and in both cases a small side 
chain is favored in the second position. The side chains beyond the second residue, however, appear to have 
higher flexibility in the crystalline state and form only weak interactions with the TLRs. Nevertheless, these 
side chains are located within ≈0.5 nm of the TLRs and might still be able to interact weakly with the recep-
tors [97, 106].
2.2.4  Applications of TLR1/2 and TLR2/6 agonists
There is now great interest in the discovery of novel small-molecule TLR modulators, because of their poten-
tial immune stimulatory activity and value as adjuvants in immunotherapy [107–115]. Several TLR2 ligands 
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have undergone clinical testing in vaccine formulations [116]. For example, a synthetic lipopeptide related to 
the naturally occurring MALP2 lipoprotein is currently in clinical trials in combination with the nucleoside 
analog gemcitabine for the treatment of pancreatic cancer [117, 118]. The lipopeptide should activate DCs to 
express co-stimulatory molecules and promote type-1 T helper responses. This lipopeptide is diacylated and 
so interacts with TLR2/6. The structure of the complex is expected to be very similar to that with the synthetic 
ligand Pam2CSK4, since only the peptide side chain after Ser2 is different between the two lipopeptides.
2.2.5  Accessory proteins involved in TLR2 signaling
The mechanism(s) by which TLRs recognize PAMPs on the cell surface appears to involve additional mem-
brane-associated accessory proteins [119]. For example, CD36 was shown by mutagenesis to play an important 
role in signaling through TLR2 on macrophages by the diacylated lipopeptide MALP2 [120]. CD36 is a member 
of the scavenger receptor type B family, and has been implicated in the recognition of oxidized LDL particles 
and the uptake of fatty acids. CD36 also appears to facilitate recognition of diacylated lipoproteins by TLR2/6. 
CD36 has an established role in the recognition of endogenous ligands and might therefore represent a sign-
aling bridge between endogenous ligands and the PRRs of the innate immune system [121]. No structural data 
is available so far for CD36, and no direct binding studies with lipopeptides have been reported.
Another mediator of lipoprotein signaling is the GPI-anchored glycoprotein CD14, which is highly 
expressed on monocytes, macrophages, and neutrophils. CD14 is best known for its role in sensitizing cells to 
the presence of Gram-negative bacterial LPS, by delivering this molecule to the TRL4 signaling complex (vide 
infra). Membrane-bound CD14 shuttles LPS to TLR4 complexes, whereas a soluble form of CD14 enables cells 
that lack endogenous CD14 to respond to LPS [122, 123]. However, CD14 is also capable of binding to a wide 
variety of natural and synthetic acylated ligands, in addition to LPS. For example, CD14 has been shown to 
enhance cellular inflammatory responses to a variety of acylated agonists of TLR2, including bacterial lipo-
proteins. The binding of soluble CD14 to Pam3CSK4 has been demonstrated with affinities in the low micro-
molar range. Moreover, CD14 was shown to enhance signaling by triacylated lipopeptides through the TLR1/2 
heterodimer in a whole cell assay [124]. It was suggested that binding of triacylated lipopeptides to CD14 may 
be the first step in the signaling pathway through TLR1/2. After binding of lipopeptide, the complex with 
CD14 should interact with TLR1 and TLR2 at the cell surface, with transfer of the lipopeptide to the signaling-
competent TRL1/2 heterodimer complex [125]. Recent in vitro studies support roles for CD14 and LPS-binding 
protein in driving binding of TLR1/2 to lipoproteins [126].
The crystal structures of mouse and human CD14 have been reported, although the latter structure is only 
to 0.4 nm resolution [127, 128]. Both proteins contain ≈11 tandem LRRs and adopt an overall horseshoe-like 
shape typical of related LRR-family members. The binding site for LPS on CD14 has been intensively studied 
by mutagenesis and by epitope mapping of antibodies that block LPS binding [129]. This study highlighted a 
region near the N-terminus, which contains a large hydrophobic pocket, likely for LPS binding, and possibly 
also for binding related lipophilic ligands such as triacylated lipopeptides. A co-crystal structure of CD14 
bound to one of its lipophilic ligands has not yet been reported, and it is so far unclear structurally how CD14 
interacts with TLR1/2.
2.3  Structures of TLR3
Double-stranded RNA (dsRNA) is a molecular pattern associated with viral infection that is specifically recog-
nized by TLR3. dsRNA is produced by most viruses at some point during their replication, although dsRNA of 
nonviral origin has also been shown to stimulate TLR3 signaling. Other receptors, however, are also capable 
of responding to viral dsRNA in mice and humans, indicating a redundancy in mechanisms used to recognize 
this PAMP [130]. Binding of dsRNA to TLR3 leads to stabilization of a homodimeric TLR3-dsRNA complex that 
signals via TIR domains facing the cytoplasmic side of the endosomal membrane (Fig. 2). TLR3 consists of 
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Fig. 13 Structure of TLR3 ectodomain. The LRR-NT and -CT modules, at the N- and C-termini, are highlighted.
an ECD containing multiple LRRs, a single transmembrane domain, and an intracellular TIR domain. TLR3 
is distinct from other TLRs in that it does not depend upon MyD88, but rather uses TRIF for signaling [131]. 
The TRIF-induced intracellular signaling pathway leads to activation of genes for secreted antiviral immu-
nostimulatory cytokines, in particular, the type-I interferons.
The horseshoe-like shape of the TLR3 ECD was first revealed in crystal structures of the monomeric 
protein [77, 78]. The large curved solenoid has an inner diameter of ≈4.2 nm and an outer diameter of 9 nm 
(Fig. 13). As with other LRR proteins, the concave inner face consists of a large parallel β-sheet, composed of 
β-strands from 23 adjacent LRRs. The solenoid has a rather flat surface, devoid of any twist. At its N-terminus, 
the LRR-NT motif consists of a disulfide cross-linked β-hairpin, whereas the C-terminal capping domain (LRR-
CT) forms a compact folded structure stabilized by two disulfide bridges.
dsRNA, but not dsDNA nor single-stranded (ss)-RNA, induces homodimerization of the purified TLR3 
ectodomain [79]. The minimum length of RNA needed for binding and homodimerization is ≈45 bp, and the 
pH optimum for binding is below 6.0, likely reflecting the slightly acidic environment inside endosomes. A 
crystal structure of the TLR3-dsRNA complex contains the bound RNA in a typical A-DNA-like double helical 
structure, sandwiched between the two TLR3 ectodomains (Fig. 14a) [80]. The overall structure of the ecto-
domain in the dimer complex is not changed significantly from that of the monomeric form. The homodi-
meric complex again has an overall “m” shape, with the N-termini at the outer sides and the C-termini 
converging at the center of the “m”. However, the mechanism of ligand recognition is unique. In the TLR3-
dsRNA complex, the straight rod-shaped ligand makes contact with both TLR3 chains at the outer N-termini 
(LRR-NT and LRR1-3 modules) and at the inner C-termini (LRR19-21 and the LRR-CT modules). The distance 
between the N-terminal binding sites is ≈14 nm, which corresponds to about 3.5 helical turns of RNA. This 
explains why the length of the RNA double helix needs to be at least ≈45 bp on each strand. Mostly, the 
phosphodiester backbone makes critical interactions with both TLR3 chains, whereas the base pairs, and 
hence the sequence of the RNA, does not (Fig. 14b). This is consistent with the known sequence independ-
ence of RNA binding to TLR3. The only place where the two TLR3 monomers make direct contact with each 
other is through largely polar side chains in the centrally located LRR-CT modules, but the interface surface 
area is only 574 Å2.
dsRNA molecules both shorter and longer than ≈45 bp can bind to TLR3, although for shorter dsRNAs 
the affinity is much reduced [79]. It seems likely that multiple TLR3 dimers can bind to very long dsRNA 
molecules. However, a different mode of interaction has been proposed to account for binding of short ≈20 nt 
dsRNA molecules to TLR3, although the models remain to be confirmed by structural analyses [132]. The 
binding of various synthetic analogues of dsRNA to TLR3 has been studied [133], including so-called polyI:C, 
which consists of a chain of polyriboinosine (poly I) hybridized with a complementary strand of polyribo-
cytosine (Fig. 15). PolyI:C was initially discovered as a potent inducer of type I interferons (IFNs) [134]. A 
less-toxic analogue is poly(I:C12U), containing a uridine at every 13th monomer position. As an inducer of IFN, 
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Fig. 14 dsRNA:TLR3 signaling complex. (a) Mouse TLR3 ectodomains form a dimer on the dsRNA. (b) The dsRNA binding sites of 
TLR3. Residues within contact distance to the dsRNA include, at the C-terminal site, Asn515, Asn517, His539, Asn541, and Arg544, which 
are all well conserved in vertebrates. The N-terminal interaction site is formed by His39, His60, Arg64, Phe84, Ser86, His108, Glu110.
Fig. 15 Structure of a cross-strand I:C base pair.
poly(I:C12U) has potent antiviral and immunomodulatory properties, which arise due to its ability to signal 
through TLR3 [135]. Poly(I:C12U), under the names Ampligen and Rintatolimod (Hemispherex Biopharma), 
has been developed clinically as an experimental immunomodulatory dsRNA drug [118]. A closely related 
immunostimulatory drug under development is Poly-ICLC, which contains PolyI:C stabilized with poly-lysine 
(called Hiltonol, Oncovir Inc.) [116].
2.4  Structures of TLR4
TLR4 and the coreceptor MD-2 comprise the physiological receptor for LPS. LPS is a complex glycolipid and 
the major component of the outer leaflet in the OM of most Gram-negative bacteria (Fig. 16). The structure 
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Fig. 16 Generic structure of LPS and lipid IVa from E. coli, and the synthetic antagonist Eritoran. No outer O-antigen polysac-
charide is shown. Abbreviations: GlcN, 2-amino-2-deoxy-d-glucose; Kdo, 3-deoxy-d-manno-2-octulosonic acid; Hep, l-glycero-
d-manno-heptose; Glc, D-glucose; Gal, d-galactose.
of LPS is highly variable, not only between different Gram-negative bacteria and different strains of the 
same bacteria, but can also vary within one strain depending upon growth conditions [136]; for example, 
depleting metal ions in the media, or growth in the presence of cationic host defense peptides (products 
of the innate immune system) can lead to rapid modification of LPS [137]. However, a common “lipid 
A” moiety can be recognized in all LPS molecules, which contains a bis-glucosamine disaccharide to 
which are typically attached 5–6 ester- and amide-linked lipid chains, as well as two phosphate groups, 
and sometimes other polar groups, such as phosphatidyl-ethanolamine (PE) and 4-amino-4-deoxy-l-ara-
binose (Ara4N) (Fig. 16). Lipid A is not found naturally, but is released from LPS by mild acid hydrolysis. 
The lipid A moiety is linked to a carbohydrate core domain, typically comprising ≈6–8 sugar residues, 
including Kdo (3-deoxy-d-manno-oct-2-ulosonic acid) and Hep (l-glycero-d-mannoheptose), which are 
not generally found on mammalian cells. The core domain is then linked either to a long oligo-saccharide 
chain or to a highly immunogenic O-antigen polysaccharide, composed of repeat units that can be highly 
variable between different serotypes. The O-antigen is the most exposed segment of LPS on the bacterial 
cell surface. Overall, the LPS layer in the OM constitutes a major permeability barrier, which severely 
restricts diffusion of substances (e.g., antibiotics) across the OM and into the bacterial periplasm and 
cytoplasm.
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LPS can stimulate a powerful immune response by signaling through TLR4. If the response is overwhelm-
ing and uncontrolled, this immune protection mechanism can lead to fatal septic shock. LPS is extracted from 
the bacterial membrane and transferred to TLR4 by two accessory proteins, the LPS-binding protein (LBP) 
and CD14 [119]. Membrane-bound CD14 shuttles LPS to TLR4/MD-2 complexes at the cell surface, whereas a 
soluble form of CD14 enables cells that lack endogenous CD14 to also respond to LPS [122, 123]. Early work 
showed that the lipid A region is responsible for most of the immunostimulatory activity of LPS. The number 
of lipid chains has a large influence on inflammatory activity. Lipid A with six lipid chains has optimal inflam-
matory activity, whereas with five chains the lipid A is ≈100-fold less active. With only four lipid chains, as 
found in lipids IVa and Eritoran (vide supra), the glycolipid typically has antagonist activity [138]. The mouse 
TLR4 complex appears to be more promiscuous in recognizing different forms of lipid A than human TLR4, 
and seems even to interact with the anticancer drug taxol [139]. However, minor changes in LPS structure can 
have large effects on immunostimulatory activity and even abolish endotoxic effects [140, 141].
2.4.1  The human MD-2/lipid IVa complex
MD-2 is a ≈18 kDa secreted glycoprotein, which alone, as well as in the complex with TLR4, binds LPS with 
nanomolar affinity [85]. The number and length of the acyl chains have an important influence on signaling 
through the TLR4/MD-2 complex. For example, Escherichia coli lipid A is usually hexa-acylated and acts as a 
potent activator (agonist) of all mammalian cells. In contrast, tetra-acylated lipid A such as lipid IVa (Fig. 16), 
the biosynthetic precursor of E. coli LPS, acts as an agonist on mouse and as an antagonist (with antiendo-
toxic) activity on human cells [142]. Lipid IVa does not induce formation of the human TLR4/MD-2 heterodi-
mer complex, as required for signaling activity.
The first structural insight into how lipid A is recognized by MD-2 came from crystal structures of human 
MD-2 bound to lipid IVa [143]. MD-2 comprises a single immunoglobulin domain stabilized by three disulfide 
bonds. The protein consists of two β-sheets, one of three antiparallel β-strands, and the other of six antiparal-
lel β-strands (Fig. 17a). Between the two sheets is a large, hydrophobic cavity with a volume of ca. 1710 Å3. The 
overall structure is rather like a partly open clam, with the two shells represented by the two β-sheets. The 
four lipid chains of the ligand insert through the opening into the main body of the clam. In a crystal structure 
of MD-2 without bound lipid IVa, the MD-2 structure is not altered significantly; the lipid A binding pocket is 
still present, but is occupied by three myristic acid molecules that appear to have been co-purified and co-
crystallized with MD-2. The lipid chains at positions 2 and 3 in lipid IVa are mostly fully extended and reach far 
into the hydrophobic binding pocket of MD-2 (Fig. 17b). The 2′ and 3′ lipid chains have a distinctly curved con-
formation. The fatty acid chains in the cavity are packed next to each other and interact through van der Waals 
contacts. The size of the hydrophobic binding cavity is not large enough to accommodate the two additional 
lipid chains present in lipid A (and LPS). Rather, one of the additional lipid chains is found on the surface of 
MD-2 where it forms part of the contact interface with TLR4 in the TLR4/MD-2/LPS complex (vide supra).
Fig. 17 Structure of MD-2 with lipid IVa. (a) The four lipid chains of lipid IVa are buried between the two β-sheets in MD-2. (b) 
Surface representation of the complex. (c) Interactions between MD-2 and the head group [sugars (green/red) and phosphates 
(yellow/red)] of bound lipid IVa.
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Fig. 18 Structure of the 1:1 TLR4/MD-2 complex with bound Eritoran (see text).
The 1- and 4′-phosphate groups and the two sugar residues in lipid IVa are at the solvent-exposed surface, 
in the opening of the clam-like structure. Here, hydrogen-bonding interactions occur between amide and 
ester carbonyls of the ligand and the edge of the β7 strand in the three-stranded β-sheet (Fig. 17c). Residues 
from Phe119-Gly123 are important for LPS recognition, and these residues with the exception of Lys122 are highly 
conserved in MD-2. Overall, the entrance to the hydrophobic cavity has a positive electrostatic surface, which 
likely aids binding of the negatively charged ligand. However, neither of the phosphate groups is involved in 
close electrostatic contacts with atoms of MD-2.
2.4.2  The human TLR4/MD-2 with bound Eritoran
Eritoran (or E5564) is a synthetic molecule related to the lipid A of the nonpathogenic LPS of Rhodobacter 
sphaeroides, with antagonist activity on human TLR4/MD-2. Eritoran contains a bis-glucosamine backbone 
linked via amide or ether bonds to four lipid chains, one containing a cis-double bond, as well as two phos-
phate groups (Fig. 16). However, neither Eritoran nor lipid IVa induces formation of the TLR4/MD-2 dimeric 
signaling complex (vide supra). The human MD-2 was crystallized with a hybrid hTLR4-hagfish-VLR fusion 
protein as a stable 1:1 complex, with Eritoran bound to MD-2 (Fig. 18) [102]. All four lipid chains in Eritoran 
are buried inside MD-2 and so are not available for interactions with TLR4. The glucosamine backbone in lipid 
IVa and Eritoran are superimposable when bound to MD-2. The shape of the lipid-binding pocket on MD-2 is 
essentially unchanged in the complexes with the two antagonists. Eritoran was in clinical development for 
use as a therapeutic against severe sepsis, however, the compound was recently withdrawn following incon-
clusive phase III trials [111, 118].
2.4.3  The human TLR4/MD-2/LPS complex
LPS is extracted from the bacterial membrane and transferred to TLR4/MD-2 by LPS-binding protein and 
CD14. The crystal structure of the TLR4/MD-2/LPS complex has been very valuable in understanding 
ligand binding specificity and the mechanism of receptor activation. Interestingly, the signaling complex 
seen in the crystal structure is composed of two copies of TLR4/MD-2/LPS arranged in a symmetrical 
fashion (Fig. 19) [144].
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Fig. 19 Structure of the dimeric TLR4/MD-2/LPS signaling complex. TLR4 chains, blue; MD-2 chains, orange; lipid A, red; and 
outer sugar/phosphates, pink (see Section 2.4). (a) viewed from the side (membrane at the bottom), and (b) viewed from the top.
The two TLR4 chains each adopt a horseshoe-like shape, as seen with other TLRs, resembling in the 
complex the letter “m”, with both C-termini in the center and the N-termini located at each side of the “m” 
(Fig. 19). The two TLR4 chains contact each other in the center through LRR modules 15–17. MD-2 again has 
a clam-like shape composed of two antiparallel β-sheets, between which the hydrophobic lipid chains of 
LPS can bind. The two MD-2 chains are situated close to the center of each arm of the “m”. Each MD-2 makes 
contact with the side of one TLR4 chain and the exposed convex face of the other TLR4 chain. The number-
ing system used for the lipid chains (R2, R3, R2′, R3′, R2″, and R3″) of the lipid A moiety is shown in Fig. 16.
Five of the six lipid chains of the lipid A are completely buried inside the hydrophobic pocket on 
MD-2, between the two β-sheets. However, the R2 chain is on the surface of MD-2 (Fig. 20a). This composite 
Fig. 20 Structure of the dimeric TLR4/MD-2/LPS signaling complex. (a) Five lipid chains of LPS are buried and one (R2) is on the 
surface of MD-2. (b) The TLR4/MD-2 interface. (c) LPS sugar–TLR4 interactions.
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(protein + lipid) surface forms a largely hydrophobic interface with one TLR4 chain (TLR41). Hence this lipid 
chain, and its key position, are likely important for the stability of the complex. Some of the ester and amide 
groups connecting the lipid chains to the sugar residues of lipid A interact at the surface of MD-2 with one 
exposed β-strand in the 3-stranded β-sheet. The two phosphate groups of lipid A do not appear to occupy 
specific binding pockets, but sit on the surface, close to a positively charged patch formed by Lys residues on 
TLR42 and MD-2, with one phosphate close to an Arg side chain contributed by the TLR4 chain. An extended 
loop protruding from LRR module 9 on the concave face of TLR42 forms part of an extensive protein–protein 
interface (PPI) with MD-2 (Fig. 20b). Finally, another extensive PPI is found between the C-terminal regions of 
both TLR4 chains at the center of the “m” formed by LRR modules 15–17.
Apart from the lipid A moiety, five additional sugar residues are seen in the complex, interacting in par-
ticular with a Tyr and several other side chain from TLR42 (Fig. 20c). However, the Kdo III sugar of the inner 
core of LPS and all carbohydrates in the outer core are not clearly visible in the electron density map, presum-
ably due to disorder resulting from a lack of fixed interactions in the crystal lattice.
Of special interest is a comparison of the TLR4/MD-2/LPS signaling complex with structures of MD-2 
bound to the two antagonists, Eritoran and lipid IVa, which reveal similarities as well as some key differ-
ences. The structures of MD-2 bound to the two antagonists reveal a large hydrophobic pocket completely 
filled by the four lipid chains of each antagonist. The size of the pocket is unchanged in the TLR4/MD-2/LPS 
complex, although the LPS now has six lipid chains. In order to create additional space for lipid binding, the 
bis-glucosamine backbone is displaced upwards by ≈0.5 nm, which repositions the phosphate groups such 
that they can interact with positively charged residues of both TLR4 chains (Fig. 21). This appears to be impor-
tant for dimerization and activation of the complex. However, the bis-glucosamine backbones of the two 
antagonists are not only translated, but also rotated by ≈180°, thereby interchanging the positions of the two 
phosphate groups. The two phosphate groups in the lipid A greatly influence the endotoxic activity of LPS 
[145]. Deletion of either phosphate group reduces endotoxic activity by ≈100 fold. The resulting monophos-
phoryl lipid A (MPL) is only a weak activator of the innate immune response. An MPL based upon lipid A from 
Salmonella minnesota was shown to selectively activate the less inflammatory TLR4-TRAM-TRIF intracellular 
signaling pathway rather than the TLR4-Mal-MyD88 pathway [146]. Hence, lipid A modifications can influ-
ence innate immune responses by mediating the recruitment of distinct sets of adaptor proteins in the cyto-
plasm. These results suggest that the MPL ligand has not only a lower affinity, but it also induces a structural 
rearrangement of the TLR4-MD-2 receptor complex. The effects are likely mediated by the observed interac-
tions of the 1- and 4′-phosphate groups with a cluster of positively charged side chains from TLR41, TLR42, 
and MD-2. This likely explains why deletion of one phosphate can have a major impact on the LPS–receptor 
interaction. It is also interesting to note that many bacteria have evolved enzymes that alter their lipid A struc-
ture, not only by modifying the number of acyl chains but also by attaching other polar/charged groups to 
the phosphates (such as phosphoethanolamine and 4-amino-4-deoxy-l-arabinose). Such modifications have 
Fig. 21 Structural comparison of LPS and antagonists bound to MD-2. The MD-2 chains are superimposed. The relative posi-
tions of LPS and Eritoran (left), and LPS and lipid-IVa (right) are shown.
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a major influence on the host response elicited by bacteria and may be an important factor in determining the 
outcome of infectious disease [139].
Efforts to understand the lipid A–TLR4 interaction have already yielded improved vaccines. Whereas 
strong induction of the MyD88 pathway is harmful because of high production of proinflammatory cytokines, 
such as TNF-α and IL-1β, a low level of induction is beneficial for long-lasting immunity elicited by vaccines. 
One MPL derivative has recently been approved as an adjuvant in vaccines used worldwide [147]. Further-
more, the development of a wide variety of different immunostimulatory lipid A derivatives for vaccine and 
other therapeutic applications is continuing to attract great interest [107, 110, 114, 118].
2.4.4  The mouse TLR4/MD-2/-LPS and lipid IVa complexes
It was mentioned above that tetra-acylated lipid IVa shows weak agonist activity on mouse but antagonist 
activity on human cells. As discussed above, the human TLR4/MD-2/lipid IVa complex is a monomeric unit in 
the complex, whereas the signaling-competent hTLR4/MD-2/LPs complex is dimeric in the crystal. Recently, 
the crystal structures of mouse TLR4/MD-2 with bound hexaacylated LPS (from E. coli) and with lipid IVa were 
reported [148], which allow interesting comparisons to be made with the human receptor.
The mTLR4/MD-2/LPS complex also appears as a dimeric unit in solution and in the crystalline state, 
confirming that LPS binding induces dimerization of the TLR4/MD-2 complex for immune signaling (Fig. 22a). 
In contrast, the mTLR4/MD-2/lipid IVa complex appeared monomeric in solution, but in crystals a dimeric 
form of the mTLR4/MD-2/lipid IVa complex was observed (Fig. 22b). The appearance of the dimer when the 
mouse receptor is bound to lipid IVa correlates with the weak agonist activity seen with this ligand in mice. 
It seems that the dimerization interaction of two 1:1:1 mTLR4/MD-2/lipid IVa complexes is weak in solution, 
but is favored upon crystallization. Conceivably, dimerization might also be enhanced at the cell surface, 
compared to free solution, as a result of membrane anchoring, and additional interactions between the trans-
membrane and/or cytoplasmic domains of TLR4.
Of special interest in the dimeric mTLR4/MD-2/lipid IVa complex is the orientation of the phospho-glu-
cosamine backbone of lipid IVa and the location of the lipid chains (Figs. 22b and c). Lipid IVa has the same 
Fig. 22 Structural comparison of mTLR4/MD-2/LPS with mTLR4/MD-2/lipid IVa complexes. (a) Structure of mTLR4/MD-2/LPS. 
(b) Structure of mTLR4/MD-2/lipid IVa. (c) Orientations of lipid A (in LPS) and lipid IVa bound to mMD-2 in the two complexes.
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orientation in the mouse complex as that seen for lipid A in the complex with LPS, and not that seen in the 
human MD-2/lipid IVa complex (Figs. 21 and 22c). Moreover, in the complex with lipid IVa bound to hMD-2, 
all four lipid chains are buried in the internal lipid-binding cavity inside MD-2. In the complex with mTLR4/
MD-2, however, one of the acyl chains (R2) is displaced towards the surface of MD-2, leaving part of the hydro-
phobic lipid-binding pocket in MD-2 unoccupied. The R2 chain can then form part of the hydrophobic surface 
of MD-2 that interacts with a hydrophobic patch on TLR4, like that seen in the complex with LPS (Fig. 22c). 
It seems that the different hydrophobicities of the dimerization interfaces, and the different charge distribu-
tions of residues on mouse and human TLR4/MD-2 have a decisive influence upon the position and orienta-
tion of bound lipid IVa, inducing the agonist orientation with mouse TLR4/MD-2 and antagonist orientation 
with human TLR4/MD-2 [148].
2.5  Structure of TLR5
Gram-positive and -negative bacteria swim by rotating helical flagella filaments up to 15 μm long extending 
from their external surface. The rotary motor at the base of the filament is embedded in the membrane (or IM) 
and drives rotation. The filament is mostly a helical assembly of a single protein, flagellin (FliC), which forms 
a tubular structure comprising 11 strands of protofilaments. The protofilaments contain nearly longitudinal 
helical arrays of flagellin. Flagellin is, therefore, one of the most abundant proteins on the surface of many 
bacteria.
The crystal structure of a 41 kDa Salmonella flagellin fragment (residues 53–450 of the 494-residue FliC) 
that does not form filaments, revealed not only the structure of the monomer, but also the likely packing of 
monomers into pairs of antiparallel straight supercoiled protofilaments in the crystalline state [149]. The FliC 
structure has an overall boomerang-like shape, which can be divided into three domains (Fig. 23). One wing 
of the boomerang is the D1 domain, which comprises three α-helices and an extended β-hairpin, where two 
helices (αND1a, αND1b) and the hairpin are contributed by the N-terminus and the third helix (αCD1) by the 
extreme C-terminus of the protein. Domain D2 at the center of the boomerang also comprises two segments 
(Lys177-Gly189 and Ala284-Ala401) and is largely composed of β-structure. A central fragment from Tyr190-
Val283 makes up domain D3 and the other wing of the boomerang. Since neither vertebrates nor plants 
contain flagella, the presence of flagellin serves as a marker of bacterial infection in both classes of organ-
ism. TLR5 is the major pattern recognition receptor used to detect flagellin, and is the only protein-binding 
TLR that is conserved in organisms as diverse as fish, flies, plants, and mammals [150]. TLR5 signals through 
the adaptor protein MyD88. Activation of the receptor mobilizes the proinflammatory nuclear transcription 
factor NF-κB in epithelial cells, monocytes, and dendritic cells, and stimulates TNF-α production.
Recently, the crystal structure of an engineered zebrafish TLR5 ectodomain in a complex with a truncated 
fragment of Salmonella FliC was reported [83]. The chimeric receptor contains 14 N-terminal LRR modules 
Fig. 23 Structure of flagellin (FliC) fragment (residues 53–450 of the 494 residue FliC). (a) Domain D1 (blue), domain D2 (green), 
domain D3 (yellow). (b) Crystal packing of the FliC fragment in two orthogonal views. The repeat distances are labeled.
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fused to a C-terminal fragment of hagfish VLR. In the TLR5-FliC complex, the FliC D1 domain is located on the 
lateral side of one TLR5 chain forming an extensive “primary binding interface” that defines a 1:1 heterodimer 
(Figs. 24a and b). Two such heterodimers further oligomerize to a symmetric 2:2 complex, where TLR5 from 
the first heterodimer makes additional, less extensive interactions with both FliC′ and TLR5′ from the second 
heterodimer, so forming a “secondary dimerization interface” (Figs. 24a and b). Thus, flagellin binding results 
in the assembly of two TLR5 chains into a tail-to-tail organization that juxtaposes the C-terminal regions in 
the center, as seen in the “m”-like structures formed by other TLR-ligand complexes. However, the ligand-
receptor stoichiometry and ligand-binding arrangement observed is unique to the TLR5 signaling complex. 
The FliC–TLR5 interface also coincides with residues involved in FliC oligomerization in the flagellar filament 
structure, and is therefore well conserved across bacterial species.
The chimeric TLR5 ectodomain consists of an N-terminal β-hairpin-capping motif (LRR-NT), 13 com-
plete LRR modules, and two residues from LRR14. Only domain D1 of flagellin is involved in direct contacts 
with TLR5. The primary interface is formed between one side of the three long helices of FliC in domain D1 
(αND1a, αND1b, and αCD1) and a lateral surface of TLR5 comprising LRRNT to LRR10, with 1320 Å2 of buried 
accessible surface area on each side (Fig. 24d). This interface can be described as two adjacent, spatially 
separated surfaces, denoted sub-interfaces A and B (and A′ and B′) (Fig. 24b). The interface A/A′ has 530 Å2 
buried surface area provided by LRRNT to LRR6, with mainly hydrophilic interactions, with five H bonds 
and three salt bridges. The sub-interface B/B′ is provided by LRR7-10 on TLR5 and the upper part of αND1a 
and αND1b on FliC. This interface is also mainly hydrophilic and is largely located in a protruding loop in 
LRR9 that undergoes structural rearrangement upon FliC binding. An LRR9-loop deletion mutant of TLR5 
is severely impaired in FliC binding [83]. Overall, residues in domain D1 make substantial contributions to 
Fig. 24 Structure of the engineered 2:2 TLR5/FliC complex. (a) Two TLR5 chains (pink and orange) oriented tail-to-tail interact 
with two FliC (green and gray). (b) The 1:1 complex is mediated by the primary binding interface, and its homodimerization to 
the 2:2 complex by the secondary dimerization interface. (c) The TLR5 structure in the complex with LRR modules numbered. (d) 
The FliC structure with labeled helices involved in the binding interfaces.
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both high affinity binding and TLR5 signaling. The conserved D1 domain is exposed in monomeric flagellin 
but is buried in the polymerized flagellin fibre, suggesting that TLR5 recognizes flagellin monomers that are 
released upon depolymerization of flagellin fibres.
A secondary dimerization interface contains interface α (TLR5-FliC), its 2-fold symmetry-related interface 
α′ (TLR5-FliC′), and interface β (TLR5-TLR5′) (Figs. 24b and c). No direct contacts are seen between the two 
FliC molecules in the complex. Dimerization interface α is located on the convex side of TLR5′ LRR12/13 and 
on the FliC C-terminal αND1b region and following loop at the bottom of the D1 domain. Dimerization inter-
face β, with 550 Å2 buried surface area, is formed mainly by the two TLR5 chains, on the ascending lateral 
side of LRR12/13.
There has been great interest in exploiting the TLR–flagellin interaction to design new vaccine adju-
vants and antagonistic therapeutics for hyperinflammatory diseases. For example, the protein drug CBLB502 
is a pharmacologically optimized derivative of Salmonella flagellin, designed for use as a radioprotectant 
in cancer radiotherapy by acting as a TLR5 agonist with reduced immunogenicity and toxicity [151]. This 
drug contains the complete domains D0 and D1 formed by N- and C-terminal regions of flagellin (1–176 
and 402–505), linked by a flexible 16-residue Gly-rich linker. This construct includes the three long helices 
(αND1a, αND1b, and αCD1) and β-hairpin present in domain D1. The construct can be produced in E. coli 
and retains the NF-κB-inducing activity and stability of flagellin, but is substantially less immunogenic. 
In another example, flagellin has been fused genetically to various protein antigens to generate chimeric 
fusion proteins that are significantly more immunogenic than achieved simply by mixing the antigen with 
flagellin [152–154]. This approach exploits the adjuvant activity expected from a TLR5 agonist, including 
induction of DC maturation, and up-regulation of cytokines, co-stimulatory signals and antigen-presenting 
molecules [155].
2.6  TLRs 7, 8, and 9
TLRs 7, 8, and 9 are involved in the recognition of viral and bacterial nucleic acids, and like TLR3 are located 
in endosomal membranes with the ectodomains facing inside the endosome. This localization is important 
in directing responses to pathogens while avoiding activation by self-nucleic acids in the cytoplasm. Indeed, 
recognition of self-nucleic acids by these TLRs can contribute to the pathology of autoimmune diseases, 
such as rheumatoid arthritis and systemic lupus erythematosus [156]. Perhaps most striking is the complex 
pathway by which these TLRs are transported from the endoplasmic reticulum to endolysosomal compart-
ments, a pathway that includes an essential processing step by endosomal proteases, involving cleavage of 
the ectodomain within the so-called Z-loop [157–159].
The amino acid sequences of TLRs 7, 8, and 9 suggest that they form a subfamily, with structural fea-
tures different from the TLRs discussed above. Each ectodomain contains  > 800 residues comprising about 
25 LRRs, with large insertions in LRRs 2, 5, 8, 11, 18, and 20 after each consensus β-strand. These insertions 
form loop structures that are predicted to protrude onto the same lateral face of the receptor [70, 160]. In 
addition, each ectodomain contains an insertion of ≈30 residues between LRR14 and 15, called the Z-loop. 
The ectodomains of these TLRs are cleaved within the Z-loop by an endosomal protease with the result that 
no full-length protein is usually detectable in the endosome compartment where ligand recognition occurs 
[157–159].
Both TLR7 and TLR8 recognize uridine- and guanosine-rich single-stranded RNA (ssRNA) from various 
viruses, as well as small interfering RNAs [161, 162]. However, TLR7 and 8 also mediate the recognition of 
self-RNA that is released from dead and dying cells, and so contribute to the pathogenesis of autoimmune dis-
eases. Several small-molecule activators of TLR7 and TLR8 have also been discovered [163, 164]. For example, 
imidazoquinoline derivatives, such as resiquimod (R848), are recognized by human TLR7 and TLR8 [164], 
whereas guanosine nucleotide analogs such as loxoribine and other imidazoquinolines, such as imiquimod 
(R837), activate TLR7 (but not TLR8) (Fig. 25) [163, 165, 166]. These imidazoquinolones are some of the small-
est TLR ligands known, and are attractive therapeutic agents for various infectious diseases. By activating 
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immune cells they induce the synthesis of IFN-α and other cytokines in a variety of cell types. As TLR acti-
vators, they have potent antiviral and antitumor properties [163]. Imiqimod (R837) has been approved for 
treatment of external genital warts caused by human papillomavirus, actinic keratosis, and basal cell car-
cinoma, and is also under investigation for treatment of other cancer types. Resiquimod (R848) was under 
development for the treatment of genital herpes, but these efforts were suspended in late clinical trials due 
to inadequate efficacy [113].
TLR9 recognizes single-stranded DNA with unmethylated CpG (the p simply denotes the phosphodiester 
bond) sequences, which are under-represented and selectively methylated in the mammalian genome and 
therefore serve to alert DCs to the presence of viral and bacterial DNA [2, 167, 168]. In mice, optimal immune 
activation requires a CpG motif flanked by two 5′ purines and two 3′ pyrimidines (e.g., GACGTT), whereas 
in humans the optimal motif is GTCGTT [169, 170]. CpG DNA is known to be an excellent immune adjuvant 
in various murine disease models and to drive TH1 immune responses. Synthetic CpG oligodeoxynucleotide 
(ODN) agonists for TLR9, therefore, have great potential in therapy [170, 171]. Several classes of CpG ODNs 
are known, varying in nucleotide sequence, single- or double-stranded, varying CpG content and content of 
phosphorothioate internucleotide linkages. Class B CpG ODNs have attracted most interest clinically. They 
are single-stranded and fully phosphorothioated in order to confer resistance to nuclease degradation and 
promote ODN uptake. B-ODNs are now in late-stage clinical trials as vaccine adjuvants to enhance immune 
responses against infectious diseases and cancer [171]. It is well established that activation by CpG ODNs 
requires TLR9, but it was unclear how B-ODN administered externally gains access to the receptor ectodo-
main inside lysosomes. Recent studies suggest that DEC-205 (CD205) is a key cell surface receptor involved in 
the uptake of B-ODN, thereby facilitating stimulatory activity in DCs and B cells [172].
Before ligand binding, TLRs 7–9 exist as preformed dimers. Ligand binding then causes conformational 
changes that result in receptor activation [82]. This preformed dimer model contrasts with the ligand-induced 
dimerization mechanisms seen with other TLRs [74, 75, 80, 83, 144]. After ligand binding to the ectodomains, 
downstream signaling is initiated and transmitted to the nucleus, first through recruitment of the cytoplas-
mic adaptor molecule MyD88. Finally, the transcription factors NF-kB and AP-1 are activated, which leads 
to up-regulation of proinflammatory cytokine genes, including those for TNFα, IL-6, and IL-12. In addition, 
signaling can occur via IFN-regulatory factors, which leads to IFN-α gene transcription. However, the TLR 
types in different cell types can respond to agonists in different ways, resulting in diverse proinflammatory 
cytokine production profiles.
Fig. 25 Structures of synthetic ligands for TLR7 and TLR8.
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Fig. 26 Structures of human TLR8. (a) Monomer structure of the hTLR8-CL097 complex. (b) Side view of the inactivate TLR8 
dimer. (c) Activated state after binding ligand CL097 (see also Fig. 28). The distance between the Cα atoms of the C termini is 
shown.
2.6.1  Structure of TLR8
Recently, the first crystal structure of a member of this TLR subfamily was reported, that for human TLR8, 
both as unliganded preformed dimer and as a ligand-induced activated dimer [160]. The complete ectodo-
main of hTLR8 (residues 27–827) used for crystallization appears as two fragments of 60 and 50 kDa by SDS 
PAGE, corresponding to N-terminal (residues 27–457) and C-terminal (residues 458–827) fragments, due to 
Z-loop cleavage inside the producing cells (Fig. 26). However, the fragments of each chain remain associated 
in the native purified protein.
Rather than having the horseshoe-like shape seen for the TLRs described so far, the number of LRRs in 
each ECD of TLR8 is large enough to generate a complete ring structure with inner and outer diameters of 
3.5–4.5 and 7–8 nm, respectively (Fig. 26a). Residues at the N-terminus of TLR8 thus interact directly with 
others at the C-terminus of the ECD through hydrogen bonding and hydrophobic contacts. The overall shape 
is rather like a doughnut with a single cut and with the ends remaining in close proximity. The inner concave 
face comprises a circular β-sheet structure, formed by association of the β-strands in each LRR. This face is 
decorated with several glycans attached to conserved Asn side chains. Interestingly, the Z loop contains the 
part of the LRR that would normally exist as a loop/helical segment on the outer convex face of the doughnut. 
However, the cleavage site is located at the N-terminal side of the Z loop, which allows the main ≈24 residue 
portion of the loop to tuck back under the inner concave face, rather than being situated on the outer convex 
face (Fig. 26a). As a result, on the convex face LRR13 interacts directly with LRR15. At the C-terminal end of the 
Z loop, a single turn of α-helix occurs, which is stabilized by a disulfide bridge between Cys479 and Cys509 
(within LRR16). In the unliganded TLR8 dimer, the two doughnut-shaped ECDs bind to each other face-on-
face (Fig. 26b), with only a small transposition so that the holes in each doughnut are not exactly lined up. 
The C-terminal regions of the two TLR8 monomers are separated by ≈5.3 nm, which likely precludes proper 
association of the cytoplasmic domains; therefore, this dimeric structure should represent the unactivated 
form of TLR8. The insertions in LRRs 2, 5, 8, 11, 18, and 20 after each consensus β-strand form loop structures 
that protrude to the same lateral face of the ECD. Upon formation of the receptor dimer, these loops on both 
ECDs are buried at the dimer interface.
The crystal structures of TLR8 in complex with three different small-molecule agonist ligands [CL097, 
CL075, and R848 (Fig. 25)] were also determined [160]. Essentially, the same dimeric structure of TLR8 was 
observed in each of the three complexes. The two TLR8 chains within one dimer are essentially superimpos-
able (RMSD of 0.04 nm). Upon ligand binding, however, the two C-termini in the dimer are brought into closer 
proximity (≈3 nm) (Fig. 26c), which would likely enable the intracellular TIR domains to interact optimally 
and initiate downstream signaling. The dimerization interfaces of the unliganded and ligand-induced dimers 
buries ≈1290 and ≈2150 Å2 of accessible surface area on each side, with much of the difference accounted for 
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by a ligand-mediated interface (Fig. 27). Ligand-induced local conformational changes occur predominantly 
in surface loops of LRR5, LRR8, and LRR17–20. The protein–protein interface involves loops on LRR5, LRR8, 
and LRR14–20, with both van der Waals, hydrophobic, and hydrogen-bonding interactions. The ligand-medi-
ated interface is composed of residues in LRR11–14 and LRR16–18.
Two ligand molecules in each complex interact with the TLR8 dimer at the dimerization interface at 
positions related by a non-crystallographic 2-fold axis. The first is close to LRR11–14 and LRR16*–18*, and 
the second is close to LRR11*–14* and LRR16–18. Contact with each ligand is made by multiple residues from 
TLR8 and TLR8*, including face-to-face pi-stacking between the side chain of Phe405 and a benzene ring in 
the ligand (R848, CL097, and CL075). Several hydrogen bonds are also detected between heteroatoms in the 
heterocyclic ligands and residues in TLR8 (Fig. 27). The 2-propyl (CL075) or 2-ethoxymethyl (CL097 and R848) 
substituents of the ligands protrude into a small hydrophobic pocket on TLR8. These hydrophobic interac-
tions may be important for the agonist activity of ligands targeting TLR8, since R837, an imidazoquinoline 
similar to R848, specifically activates TLR7 but not TLR8, and lacks the 2-substituent in the imidazole ring.
Ligand binding leads to a reorganization of the dimer structure, and the way in which the doughnuts 
and individual LRR modules interact (Fig. 28). In the unliganded (inactivated) form, the interactions of LRR8 
and LRR18*, as well as LRR11–13 and LRR14*–15*, are the major contributors to the dimerization interface. 
After ligand binding LRR8 changes its interaction partner to LRR18*–20*, LRR18* to LRR11, and LRR11–13 to 
LRR17*–18*. Concomitantly, Phe405 in LRR13, which makes contact with Phe494* in LRR15* in the unliganded 
form, now interacts with the ligand in the liganded form. In addition, after ligand binding new interactions 
between LRR5 and LRR20* are created. This rearrangement of the complex upon binding of relatively small 
non-natural ligands is quite remarkable. The aromatic ligands are much smaller than the natural PAMPs the 
receptor has evolved to detect. Intriguingly, mutations in the receptor that abolish or reduce agonist activity 
of the small ligands, also abolished or reduced significantly signaling by ssRNA, suggesting that the small 
ligands and ssRNA share the same binding site on TLR8. However, other TLR8 side chains that surround the 
small-molecule binding site (Arg429, Tyr353, Val378) are not essential for binding the small molecule ligands, 
yet their mutation abolishes binding to ssRNA. So far, it remains unclear exactly how ssRNA interacts with 
the TLR8 dimer. Further structural studies are needed to resolve this problem.
2.7  TLRs 10, 11, 12, and 13
So far, 10 different TLRs have been identified in humans, and 13 in mice. As yet, no ligand has been iden-
tified for TLR10 from either species. However, TLR10 has been shown to form homodimers, and to inter-
act with TLRs 1 and 2 [173]. The crystal structure of the intracellular TIR domain of human TLR10 has been 
reported, in the form of a symmetric dimer most likely corresponding to the signaling competent form [174]. 
Fig. 27 Ligand recognition by TLR8. Residues involved in the interaction of TLR8 with CL097 (a), CL075 (b), and R848 (c) are 
shown.
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Fig. 28 Conformational changes in TLR8 induced by binding to agonistic ligands. The unliganded inactive form (a) is trans-
formed into the activated form (b) upon ligand binding.
TLR11 and TLR12 are both murine TLRs located in endosomal compartments, which are required to mount 
an effective protective response against the protozoan parasite Toxoplasma gondii and other phylogenetically 
related microorganisms. These TLRs, working as heterodimers, can recognize profilin-like proteins in these 
parasites [175, 176]. TLR13 is another endosomal murine TLR, which is involved in recognition of microbial 
nucleic acids, in particular, a conserved bacterial 23S ribosomal RNA sequence that includes the binding site 
of macrolide (e.g., erythromycin), lincosamide, and streptogramin group (MLS) antibiotics in Gram-positive 
bacteria, like Staphylococcus aureus [177, 178]. Moreover, modifications to the MLS sequence that give rise to 
resistance to these antibiotics in bacteria fail to stimulate TLR13, thereby linking mechanisms of antibiotic 
resistance with defective immune stimulation via TLR13 [178].
3  Structures Of C-type lectin receptors
3.1  Structures of DC-SIGN and DC-SIGNR
DC-SIGN (dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin) is a prototype type II 
transmembrane CTL found on macrophages and DCs. There it interacts with endogenous molecules, such as 
ICAM-2 and ICAM-3, as well as pathogen-associated ligands found on bacteria and viruses. DC-SIGN mediates 
endocytosis and targeting of foreign antigens to late endosomal/lysosomal compartments for degradation 
and presentation to T cells. These interactions are mediated through carbohydrates, including N-linked high-
mannose structures (typically 5–9 terminal mannose units such as Man9GlcNAc2), and branched fucosylated 
oligosaccharides that are common on parasites. Signaling through DC-SIGN influences cytokine production 
levels in response to binding pathogen-derived carbohydrates [32]. Furthermore, cooperation between innate 
signaling pathways mediated by different PRRs, such as the CLRs and TLRs, plays an important role in tailor-
ing adaptive immune responses to different pathogens. On the other hand, DC-SIGN mediated internaliza-
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Fig. 29 (a) Schematic representation of the domain organization of DC-SIGN and DC-SIGNR. (b) Repeat motifs in the neck 
region. Residues at a/d positions of the heptad repeat are highlighted. (c) The CRDs are projected and held away from the 
membrane by the neck.
tion is exploited by some pathogens to gain entry to target cells. For example, DC-SIGN is exploited by HIV-1, 
Ebola, and Dengue viruses as well as by Mycobacterium tuberculosis to facilitate entry to cells [179–182]. Thus, 
carbohydrate recognition by DC-SIGN is important for both normal immune responses and opportunistic 
exploitation of the receptor by pathogens.
DC-SIGNR (or L-SIGN) is a closely related transmembrane receptor found on endothelial cells [183]. 
DC-SIGN and DC-SIGNR share 77 % sequence identity and are closely similar in overall architecture. However, 
DC-SIGNR binds only to high-mannose oligosaccharides and does not mediate uptake and degradation of 
glycoconjugates. Thus, whereas DC-SIGN functions both in adhesion and in endocytosis of pathogens, DC-
SIGNR has only the properties of an adhesion receptor and with a more restricted set of ligands. However, 
DC-SIGNR can also serve as an entry-receptor for many of the same viruses that exploit DC-SIGN.
DC-SIGN and DC-SIGNR consist of an intracellular N-terminal domain for signaling in the cytoplasm and 
a globular C-terminal CRD that binds carbohydrate ligands. The CRD is separated from the transmembrane 
region by a neck domain that contains multiple tandem repeats (Fig. 29). The neck domain is required for 
tetramerization, which is mediated through a coiled coil that forms a parallel 4-helix bundle. This coiled-coil 
neck region generates stable tetramers and projects the CRDs in a cluster some distance away from the cell 
surface. However, the CRDs appear not to be held in a fixed position but can reorient to engage with carbohy-
drate ligands [184]. The coiled coil contains a heptad repeat sequence (denoted abcdefg, where a/d are mostly 
hydrophobic residues), which is embedded within multiple tandem repeats of a largely conserved 23-mer 
motif (Fig. 29) [183]. The side chains of the hydrophobic (a/d) residues within each heptad are buried at the 
center of the 4-helix bundle. Each motif also contains a conserved proline residue that is predicted to inter-
rupt regular helical structure. Crystal structures of the neck region of DC-SIGNR revealed a series of 4-helix 
bundles, connected by short non-helical linkers containing the conserved prolines (Fig. 30) [185–187].
Crystal structures of the CRDs from DC-SIGN and DC-SIGNR bound to a pentasaccharide (GlcNAc1β-
2Manα-[GlcNAc1β-2Manα-6]-3Man) (Fig. 31a) were reported in 2001 [188]. The pentasaccharide contains a 
central mannose linked through the 3- and 6-positions to the disaccharide GlcNAc1β-2Man1α. Whereas the 
DC-SIGN-carbohydrate complex contains a pair of CRDs bound to one oligosaccharide, the DC-SIGNR complex 
reveals a 1:1 CRD–oligosaccharide interaction (Fig. 32). In the DC-SIGN complex, one CRD forms the same 
contacts to four sugar residues as observed in the DC-SIGNR structure, but the fifth sugar residue (terminal 
GlcNAc) interacts with the partner CRD in the DC-SIGN complex. The conformation of the pentasaccharide is 
essentially identical in both structures. The internal α-1,2-linked mannose binds to the Ca2+ site found on all 
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Fig. 30 (a) Four-helix bundle of the 23-amino acid repeat motif of the neck region of DC-SIGNR. The repeat motifs are linked 
through non-helical segments, including a Pro residue. (b) Model of a neck fragment containing multiple 4-helix bundles, with 
the C-terminal CRD at the top [187]. (c) Top view of the CRD with the first 4-helix bundle [185].
Fig. 31 (a) Structures of oligosaccharides recognized by DC-SIGN and DC-SIGN/R. (b) N-Linked high mannose structure.
CTLs, with the equatorial 3- and 4-hydroxyls coordinating with the Ca2+ ion (Fig. 32). The oligosaccharide also 
makes several hydrophobic and hydrogen-bonding interactions with the rather flat ligand-binding site on 
each receptor protein. The crystal structures reveal the strong preference for binding N-linked glycans where 
the central mannose is linked in the α-form, a structural motif only found in high-mannose oligosaccharides.
Further insights into the ability of DC-SIGN to bind fucosylated ligands came from a crystal structure of 
DC-SIGN bound to the pentasaccharide lacto-N-fucopentaose-III (LNFP-III), which contains the Lewisx trisac-
charide (Fig. 33) [189]. The conserved Ca2+ at the primary carbohydrate-binding site is coordinated to the 3- 
and 4-hydroxyls of the α-1,3-linked l-fucose residue in LNFP-III (Fig. 34a). However, since these hydroxyls are 
equatorial and axial, respectively, rather than both being equatorial as seen in bound mannose (Fig. 32), the 
fucose sugar is tilted. The compact structure of the Lewisx trisaccharide is oriented with the central GlcNAc 
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Fig. 32 (a) Structure of the CRD of DC-SIGN bound to GlcNAc2Man3. Cyan spheres are bound Ca2+ ions [188]. (b) Interactions of 
the α-1-3-linked branch with DC-SIGNR. Only key sugars are shown. Ca2+ coordination is shown by blue lines, hydrogen bonds 
as dashed lines. (c) Interactions of α-1-3-linked branch with DC-SIGN. The terminal GlcNAc1 forms a cross-link by forming the 
typical CTL interaction with the principal Ca2+ site of another CRD (only coordination bonds to the Ca2+ (gray) are shown). (d) 
Interaction of the α-1-6-linked branch with DC-SIGNR, including the central (reducing) mannose (Man3).
Fig. 33 Structures of ligands used in structural studies of DC-SIGN and DC-SIGNR [189].
residue in LNFP-III pointing away from the protein and the terminal galactose residue contacting the protein 
in a secondary binding site. Various van der Waals as well as hydrogen-bonding interactions are seen between 
the bound ligand and the receptor. The structure suggests that other fucose-containing ligands may bind with 
fucose in the primary (principal Ca2+) binding site.
1518      J.A. Robinson and K. Moehle: Molecular recognition in the immune system. Part II
Fig. 34 (a) Structure of DC-SIGN bound to LNFP-III (see Fig. 33). (b) Structure of Lewisx trisaccharide bound to DC-SIGNR. Ca2+ 
coordination is shown by pink lines, hydrogen bonds as dashed lines. Cyan spheres are bound Ca2+ ions.
A crystal structure was also reported of a DC-SIGNR fragment bound to the simple Lewisx trisaccharide 
[189], although this ligand has only weak affinity for DC-SIGNR (≈mM). The position of the bound ligand is 
very similar to the position of the corresponding portion of the LNFP-III ligand bound to DC-SIGN. However, 
several key differences in ligand-protein contacts are also seen between the two complexes (Fig. 34b). A third 
crystal structure comprises a complex of the CRD of DC-SIGN bound to a branched tetra-mannose (Man4) 
(Fig. 33) [189]. The α-linked terminal reducing mannose residue is accommodated because it points away from 
the protein, indicating why binding of branched high-mannose oligosaccharides is permitted by DC-SIGN.
Further insights into binding of branched mannose carbohydrates to DC-SIGN came from crystal struc-
tures of its CRD bound to a hexa-mannose fragment (Man6, Fig. 33) of the full N-linked high-mannose oligosac-
charide (Man9GlcNAc2), as well as to the disaccharide Manα1-2Man (Table 1) [190]. These structures revealed 
the carbohydrate ligands occupying two different overlapping orientations in the crystal, in a ratio ≈75:25. The 
major orientation seen with the hexamer corresponds to the arrangement seen in earlier crystal structures 
[189], but the α-1-6 branch of the carbohydrate is not visible. The penultimate α-1-3-linked mannose that forms 
one arm of the outer-branched trimannose unit interacts with the primary Ca2+ site. In the second (minor) ori-
entation, the same mannose is bound to Ca2+, but its orientation is reversed by a 180° rotation. This rotation 
exchanges the position of the 3- and 4-OH groups so that they can still coordinate to Ca2+. In this orientation, 
only two sugars are visible in the complex; the mannose at the Ca2+ site and the non-reducing terminal α-1-2-
linked mannose. In the complex with the disaccharide Manα1-2Man, binding is only seen at the principal Ca2+ 
site; no other binding site was occupied on the protein. However, the ligand again binds in two orientations, 
related by a 180° rotation that interchanges the positions of the 3- and 4-OH groups coordinated to Ca2+.
These observations show that high-mannose oligosaccharides can interact with DC-SIGN in multiple 
orientations, with the primary energetic interaction occurring at the primary Ca2+ site, but with multiple sec-
ondary interactions occurring through neighboring binding sites. The ability of DC-SIGN (and DC-SIGNR) to 
bind high-mannose glycans in multiple orientations may facilitate multivalent binding of clusters of CRDs to 
glycans displayed in various arrangements on the surface of a pathogen. The CRDs of DC-SIGN and DC-SIGNR 
bind Man9GlcNAc2 oligosaccharide 130- and 17-fold more tightly than mannose (mannose affinity is weak – in 
the mM range), and the affinity for a glycopeptide bearing two such oligosaccharides is increased a factor of 
5- to 25-fold [191]. Moreover, closer spacing of the two oligosaccharides causes a greater increase in affinity 
to DC-SIGNR than to DC-SIGN, suggesting that the spacing of high-mannose N-linked oligosaccharides on a 
protein surface influences significantly the selectivity of ligand recognition.
Langerin is another type-II transmembrane PRR found on Langerhans cells. The ECD comprises a neck 
region that forms trimeric helical bundles, linked to a CRD at the C-terminus. The CRD binds various mono-
saccharides in a calcium-dependent manner, including mannose, fucose, and N-acetylglucosamine, as well 
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as oligosaccharides like mannan [192]. Binding of the monomeric CRD to monosaccharides is weak (≈mM 
range). However, oligomerization again facilitates multivalent, higher-affinity binding to oligosaccharides. A 
role for langerin has been proposed in internalization of both self- and non-self-glycoprotein antigens. Crystal 
structures show how the CRD from langerin interacts with mannose and the disaccharide maltose (Table 1) 
[193]. In both structures, an important determinant of monosaccharide recognition is coordination through 
the pyranose equatorial 3- and 4-OH groups to Ca2+ in the primary Ca2+ site.
3.2  Mannose-binding lectins
Mannose is found in an extensively branched multivalent format only on the surface of microorganisms. It 
is not surprising, therefore, that the innate immune system has developed mechanisms for recognizing this 
form of mannose as a PAMP. However, mannose is also found in many human glycoproteins at non-terminal 
sites and at a much lower surface density. A key role in innate defense is played by cell surface membrane 
proteins, such as the mannose receptor, which mediates phagocytosis of microorganisms by macrophages 
and DCs. In addition, soluble mannose-binding lectins in the circulation are greatly up-regulated during 
infections, and upon binding to terminal mannose on the bacterial surface, initiate antibody-independent 
complement activation.
The mannose receptor (MR) belongs to a small subgroup of the C-type lectin superfamily, which also 
includes DEC-205, Endo180, and PLA2R [25, 29, 34, 194]. The MR binds carbohydrate moieties on pathogens, 
such as bacteria, fungi, parasites, and viruses. However, the MR also binds endogenous glycosylated mol-
ecules, in particular, pituitary hormones such as luteinizing hormone and thyroid-stimulating hormone, 
influencing their circulatory half-life. Thus, the MR has multiple roles apart from its functions in the immune 
system [27, 36, 195]. The MR is preferentially expressed on DCs, tissue macrophages, and specialized endothe-
lial cells, and constitutively recycles between the plasma membrane and the early endosomal compartment.
The MR has an unusual topology, with the N-terminus outside the cell, a single transmembrane segment 
and a short C-terminal cytoplasmic domain [34]. The ectodomain contains a cysteine-rich domain at the 
N-terminus, followed by a fibronectin type-II (FNII) domain and then a series of eight C-type lectin domains 
(CTLDs 1–8) leading down to the cell membrane (Fig. 35). The Cys-rich domain binds to a variety of sul-
fated carbohydrates, including glycoproteins and hormones terminating in sulfated N-acetylgalactosamine, 
3-sulfated galactose, and fucose, as well as chondroitin-4-sulfates. The function of the FNII-domain is so far 
Fig. 35 (a) Domain structure of the mannose receptor. (b) Organization of a typical soluble mannose-binding protein.
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unclear, but the domain is predicted to adopt the canonical fold seen in other FNII domains. The MR displays 
Ca2+-dependent binding to terminal mannose, fucose, and N-acetylglucosamine residues. Only CTLD4 shows 
significant carbohydrate binding as an isolated domain, although CTLD5 retains weak sugar binding activity, 
which is consistent with the observation that only CTLD4 and CTLD5 contain the conserved residues required 
for Ca2+-dependent carbohydrate recognition [34].
Soluble mannose-binding proteins (MBPs) recognize a wide variety of branched microbial carbohydrates 
present on the surface of yeasts, bacteria, mycobacteria, and some viruses such as influenza and HIV-1 [35]. 
Human MBP is a multimeric protein consisting of a ≈32 kDa subunit, which associates into trimers and then 
into higher multimers in a “bouquet-like” array (Fig. 35). Each subunit contains an N-terminal cysteine-rich 
domain, followed by a collagen-repeat region, a neck region comprising a coiled-coil motif, and finally a CRD 
exposed on the outer surface of the bouquet that requires calcium to bind ligand. The coiled coil mediates 
formation of a trimeric parallel α-helical bundle, and the resulting trimers then assemble further into higher 
multimers, likely through association of their collagen-like domains (Fig. 35). The affinities of the isolated 
CRDs for monosaccharides are relatively low (mM range), however, the apparent affinity of the multimeric 
MBP for branched multivalent ligands is dramatically higher (nM) [196]. On the other hand, assemblies of 
lower valency, such as linear carbohydrate chains found on host glycoproteins, interact with MBPs with 
much lower affinity [197]. Crystal structures proved to be important for understanding how MBPs can distin-
guish between host and pathogen-derived mannosylated ligands, as described below.
3.2.1  Mannose-binding proteins
The crystal structures of rat and human MBP fragments, comprising the CRD and the coiled-coil neck domain, 
revealed how MBP trimers form the basic recognition unit for branched oligosaccharides on microorganisms 
(Fig. 36) [198, 199]. The neck region incorporated into both constructs was 24–30 residues long, which as 
isolated peptides show no regular secondary structure. In the context of the MBP fragment, this neck region 
adopts a parallel trimeric helical bundle, with hydrophobic residues at the a/d positions of a heptad repeat. 
The presence of the CRD domain in each chain stabilizes the trimeric structure through direct contacts with 
neighboring chains. This packing arrangement gives each CRD a well-defined orientation, and determines 
the relative spatial organization of the carbohydrate binding sites, which are located about ≈5 nm from each 
other. This relatively large distance makes it difficult for a single mammalian high-mannose oligosaccharide 
chain to interact with more than one CRD within the trimer. However, since the carbohydrate binding sites all 
Fig. 36 Trimeric unit of the human mannose-binding protein. Side (a) and top (b) views. Pink spheres are bound Ca2+ ions; sur-
rounding residues are highlighted. The coiled-coil region is red. The N- and C-termini of one chain are indicated.
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point out from the same side of the molecule, they are ideally positioned to interact with dense sugar arrays 
on a microbial cell surface.
Within each CRD, bound Ca2+ ions are important for the interaction with carbohydrate ligands. The 
primary Ca2+ ion interacts with ligand by coordinating to the 3- and 4-hydroxyls in bound mannose, as 
revealed in a crystal structure of rat mannose-binding protein A (MBP-A) complexed with a branched oli-
gomannose sugar (Table 1) [200]. Only the terminal mannose of each visible branch of the oligosaccharide 
interacts with the CRD; the rest of the carbohydrate points away from the CRD and makes limited contacts 
with the protein. Further crystal structures of MBP-A and MBP-C have been reported with various bound 
monosaccharides (e.g., mannose, N-acetylglucosamine, and fucose) and disaccharides, as well as the MBP-A 
trimer cross-linked by a high-mannose oligosaccharide (Table 1) [201, 202]. The structures reveal that the 
monosaccharides or α-1-6-linked mannose can bind to MBP-A in one orientation, whereas α-1-2- or α-1-3-linked 
mannose binds in an orientation rotated by 180° around an axis relating the 3- and 4-OH groups. In contrast, 
a similar set of ligands all bind to MBP-C in a single orientation. Each MBP seems to interact with a particular 
ligand in preferably one orientation. The protein residues that serve as both Ca2+ and sugar ligands are the 
same in both MBP-A and MBP-C. However, one residue close to the binding site (His 189 in MBP-A) appeared 
by mutagenesis to have a key influence upon the orientation of bound ligands in MBPs [202–204]. Finally, 
the crystal structure of MBP-A trimer bound to Man6GlcNAc2Asn revealed the two trimers cross-linked by the 
oligosaccharide (Table 1) [202]. The trimers are arranged in hexagonal packed sheets in the crystal with the 
sheets cross-lined by the oligosaccharide. It was suggested that this packing arrangement might indicate 
how a cell surface presenting mannose-terminated sugars (one layer of the crystal) could be recognized by a 
multimeric form of MBP-A (represented by the opposing layer).
3.2.2  The mannose receptor
The crystal structure of CTLD4 from the MR (Fig. 35) was reported in 2000, although the structure does not 
contain bound carbohydrate ligand [205]. The overall structure of the CTLD4 domain is similar to that of other 
C-type CRDs (Fig. 37a). Equivalent residues in this domain can be superimposed on those from MBP-A with an 
rmsd of 0.15 nm. Unlike the core of the domain, where the similarity is greatest, striking differences are seen 
in the size and structure of some surface loops. A rather large, extended, and flexible loop that follows the 
β2 strand is seen in CTLD4 (residues 701–734), which is absent in MBP-A. This region is stabilized in MBP-A 
by two bound Ca2+ ions, including the principal Ca2+ site that interacts with bound mannose. In the CTLD4 
structure, however, only the primary site located close to the base of the extended loop is occupied with 
bound Ca2+. Attempts to induce ligand binding by soaking crystals in high concentrations of sugar failed to 
Fig. 37 Structure of the CTLD4 domain of the MR (a) with extended loop, and comparison to rat mannose-binding protein A (b) 
[205]. Cyan sphere is a bound Ca2+ ion. Disulfide bonds are in yellow.
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reveal a binding site. It seems, therefore, that the structure present in the crystals is unable to bind the full 
complement of Ca2+ nor mannose ligands. It was speculated that the structure may be related to an intermedi-
ate that must occur physiologically in endosomes, where the slightly acidic pH could lead to loss of Ca2+ and 
de-binding of sugar ligands. The ligand and receptor then sort from one another, with the receptor returning 
to the cell surface for another round of ligand binding. Indeed, isolated MR CTLD4 displays reversible, pH-
dependent Ca2+ and sugar binding, with a mid-point in the transition around pH 5.0.
Crystal structures have also been reported of the cysteine-rich N-terminal domain of the MR, which 
plays a critical role in binding sulfated glycoproteins, including pituitary hormones [206, 207]. This globu-
lar domain of ≈130 residues adopts a β-trefoil, possessing 12 antiparallel β-strands with six forming an 
almost β-barrel-like arrangement, with the entire trefoil stabilized by three disulfide bonds (Fig. 38a). The 
structure of this domain bears no resemblance to the CRDs found in the MR and other CTLDs. The ligand, 
4-sulfated N-acetylgalactosamine (GalNAc-4-SO4) binds with a KD ≈0.1 mM with its sulfate group inserted 
into a binding pocket formed on one side by residues 111–116 in the loop between strands 11 and 12, and 
the other side by the side chains of Asn102 and Trp117, and on the bottom by the Asn99 side chain (Fig. 38a). 
The sulfate group makes extensive hydrogen-bonding and van der Waals contacts to the protein. The galac-
tose ring is positioned with the polar A-face exposed to solvent and the nonpolar B-face stacked against 
the indole of Trp117. This stacking arrangement is also seen in several other protein-galactose complexes 
[206]. The sulfate group does not interact with positively charged side chains or counter ions. Rather, the 
interactions with the protein are mediated through multiple hydrogen bonds involving peptide bond NH 
groups. This domain binds to GalNAc or galactose when it is sulfated at the C3 or C4 positions, and more 
weakly if the sulfate is at C6. The lack of discrimination between sugars with and without the N-acetyl 
group is explained by the absence of any direct contact between the NAc group and the protein. The protein 
recognizes sulfated GalNAc when it is terminal but not internal within an oligosaccharide chain, which 
again can be nicely explained by the crystal structure. Another sugar residue linked to C3 would prevent 
access of the sulfate group to the binding pocket. The anomeric center of the bound ligand points away 
from the protein surface, thus allowing attachment of another sugar at this position without causing steric 
hindrance.
Crystal structures and affinities of 3-SO4-Lewisx, 3-SO4-Lewisa, and 6-SO4-N-acetylglucosamine bound to 
the Cys-rich domain have also been reported [207]. The conformation of the protein is virtually identical in all 
crystal structures. Interestingly, a 6-SO4-Gal binds with KD ≈ 1 mM, whereas 6-PO4-Gal showed no detectable 
binding to the Cys-rich domain, suggesting that the slightly larger phosphate group is not accommodated 
within the sulfate-binding site.
Fig. 38 (a) Cysteine-rich domain from the MR (Cys-MR). Disulfides are yellow ball-and-stick. (b) Cys-MR complexed with 4-SO4-
N-acetylgalactosamine. Sulfur atom in yellow, hydrogen bonds in blue dotted lines.
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4  Structures of NOD-like receptors
Relatively few structural studies at atomic resolution have been reported on NLRs to date, nor how they rec-
ognize specific PAMPs. The crystal structure of a fragment derived from NLRX1 has been reported, but not 
bound to its RNA ligand.
4.1  RNA-binding domain of NLRX1
NLRX1 (also known as NOD9) is a proinflammatory activator that localizes to mitochondria, and stimu-
lates the production of reactive oxygen species via TNFα activation [208]. However, this receptor has a more 
complex immune modulatory function, since it can also down-regulate inflammatory responses as a negative 
regulator of RIG-1 and TLRs through interaction with mitochondrial signaling adaptors [209, 210]. Recently, 
a crystal structure was reported of the C-terminal fragment of human NLRX1 (called cNLRX1, residues 629–
975), along with evidence that this receptor interacts specifically with an RNA ligand [59].
The cNLRX1 protein contains the entire C-terminal putative ligand-binding domain comprising eight 
LRRs as well as an N-terminal 2-helix domain (LRR-NT) and a C-terminal antiparallel 3-helix bundle (LRR-CT) 
(Fig. 39) [59]. The central domain with eight LRR modules folds into a crescent shape with the parallel β-strands 
oriented on the concave side. The LRR1-LRR7 motifs have the typical LRR fold, except LRR8, which does not 
contain an α-helix on the convex side, but rather proceeds directly into the LRR-CT domain. The concave face 
encircles and docks onto one side of the LRR-CT domain. The cNLRX1 protein elutes in two fractions from a 
gel filtration column, with apparent masses corresponding to monomer (≈39 kDa) and hexamer (≈240 kDa). In 
the crystal structure, the protein assembles into a hexamer with 2-fold crystallographic symmetry and 3-fold 
non-crystallographic symmetry. Three cNLRX1 chains associate by intertwining of helical segments of their 
LRR-NT domains at the center to create the 3-fold axis. Two trimeric subunits then assemble into a hexamer, 
with the LRR-CT domains buried at the interface (Fig. 39). The LRR-CT domain plays a key role in dimerization 
and provides structural support for the LRR modules through intra- and inter-subunit interactions.
Fig. 39 Structure of cNLRX1. The monomer subunit is shown (top). The hexamer (bottom) is formed by trimerization of dimers 
(subunits A/A′, B/B′, and C/C′). The LRR modules in subunit A are labeled (adapted from [59]).
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Potential ligands for cNLRX1 have been probed by electrophoretic band-shift assays [59]. In this way, 
binding to ssRNA and dsRNA was detected with binding affinities around 1 and 0.1 μM, respectively. However, 
no binding was observed to ssDNA or dsDNA. A possible binding site for the RNA was identified around 
a large surface-exposed patch of positively charged Arg and Lys residues, which lies on one face of each 
monomer. Mutation of a key arginine within this region, Arg699, inhibits RNA binding. A model was also 
proposed for the full-length NLRX1 hexamer, in which NOD-NAD domains extend from the LRR domain and 
decorate the exterior surface of the hexamer [59]. The NOD domains might further mediate oligomerization 
into ring-like assemblies, as well as mediating binding to other interacting partners.
4.2  Pyrin domains and CARDs
NLRs containing an N-terminal pyrin domain (PYD) or a caspase activation and recruitment domain (CARD) 
form the largest group of NLRs (NLRPs), with 14 members in humans (NLRP1-14) [38, 40, 41, 48, 50]. For 
example, NLRP1 and 3 activate the inflammatory immune response by detecting cytosolic PAMPs via their 
C-terminal LRR domains. Once activated, NLRP1 and 3 oligomerize via their central NACHT domains. Finally, 
the N-terminal PYDs recruit the ASC adaptor protein, and then pro-caspase 1 molecules. The resulting multi-
component signaling complex, termed the inflammasome [48], results in autoproteolytic activation of caspase 
1, which in turn cleaves proinflammatory cytokines such as pro-IL1β and pro-IL18 into their mature forms [47].
Several PYD structures have been determined recently, by crystallography or NMR spectroscopy, includ-
ing from NLRP3 (also called NALP3) [211], NLRP1 (or NALP1) [212], the ASC adapter protein [213, 214], NLRP12 
[215], NLRP7 [216], ASC2 [217], and NLRP4 [218]. These structures reveal a high degree of conservation with 
a fold comprising a 6-helix bundle. The structures of several CARDs determined by crystallography or NMR 
spectroscopy have also been reported [214, 219–222]. These domains also adopt a compact 6-helix bundle 
structure in crystals and in solution.
5  Structures of RIG-like receptors
The RLRs are multidomain proteins (Fig. 4). RIG-I and MDA5 share a similar domain organization, comprising 
tandem N-terminal CARD domains, followed by a domain that belongs to the DExD/H-box helicase super-
family, followed by a small regulatory domain and a C-terminal RNA-binding domain (CTD) [64]. Helicases 
comprise a large superfamily of enzymes. They are nucleic acid-dependent ATPases that promote unwinding 
of dsDNA or dsRNA, and are therefore involved in many important cellular processes [223]. Helicase domains 
convert chemical to mechanical energy by coupling ATP binding and hydrolysis to protein conformational 
changes. In contrast to bona fide helicases, however, RIG-I translocates on dsRNA and recognizes the 5′-
PPP motif, which leads to large conformational changes and RIG-I activation. Recent structural studies have 
shown that activation of RIG-I occurs through an RNA- and ATP-driven structural switch in the helicase 
domain, which exposes CARDs that then mediate downstream signaling [224]. This likely occurs through 
dsRNA binding to the helicase domain, resulting in activation of the ATP-hydrolyzing function and a confor-
mational change of the complex that exposes the CARDs. The CARDs then transmit signals downstream by 
recruitment of other molecules, which leads finally to the expression of antiviral interferon-stimulated genes 
[225–227]. LPG2 has a similar domain organization, except that it lacks the CARD homology region.
Recent structural studies of RLRs (reviewed recently [228]) have provided important insights into the 
structural basis for dsRNA and 5′-PPP-RNA sensing by these receptors.
5.1  RNA recognition by RIG-I
A thermodynamic analysis revealed that blunt ended 5′-PPP dsRNA is required for maximal binding affinity to 
RIG-I [229], and the CTD provides the greatest thermodynamic contribution to binding. The helicase domain, 
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on the other hand, plays a key role in specific binding to dsRNA, rather than ssRNA. In 2008, crystallographic 
and NMR studies provided the first atomic models of the CTD domain of RIG-I [230, 231]. These results were 
followed by crystal structures of the RIG-I CTD bound to the blunt ends of a synthetic 5′-triphosphorylated 
dsRNA oligonucleotide. Interactions involving the 5′-PPP group were clearly visible in the complex, seques-
tered in a basic lysine-rich patch on the protein surface (Fig. 40) [232, 233]. The side chain of Phe853 stacks 
over both bases of the terminal base pair of the dsRNA in the complex, consistent with the requirement for 
a blunt-end duplex. Later, additional crystal structures were reported of larger fragments of RIG-I, also with 
bound nucleotide analogues, including ADP or ADP-AlF3 (a mimic of the transition state of ATP hydrolysis) 
or ADP-BeF3 (likely an ATP structural mimic), and bound 5′-triphosphorylated RNA [234–238]. These results 
provided key insights into the likely mechanism of RNA- and ATP-dependent receptor activation.
Pyle and co-workers reported crystal structures of human RIG-I in complex with dsRNA (lacking a 5′-PPP) 
and in a complex with a 5′-triphosphorylated RNA hairpin and ADP (Fig. 41) [237, 238]. This RIG-I protein 
lacked the N-terminal CARD domain (residues 1–229) and was co-crystallized first with blunt-ended duplex 
RNA. The RIG-I protein in the crystal completely surrounds the bound RNA and encloses it within an elaborate 
network of mostly polar interactions (Fig. 41). Numerous contacts are formed between 2′-hydroxyl groups on 
the RNA and protein amide groups. Helicase domain 1 (HEL1) faces the minor groove of the RNA and interacts 
with the backbone of both RNA strands. Almost half of the HEL2 domain is disordered in the structure, perhaps 
due to the absence of the CARD domains and/or ATP. An insertion domain (HEL2i) within HEL2, comprising an 
α-helical bundle, is a component of the ring that grips the dsRNA by interaction with the minor groove. HEL2i 
plays an important role in the specific recognition of RNA. Strikingly, HEL2 and the CTD are connected through 
a V-shaped structure (also called a pincer (P) motif [236]) composed of two long α-helices that make a 65° turn 
(Fig. 41), which establishes extensive interactions between HEL1, HEL2, and the CTD. Although the pincer is 
not part of the ATPase site, nor is it a direct RNA-binding site, it likely transmits information essential for RNA 
sensing between these sites. The CTD interacts with the RNA in a manner similar to that seen in previously 
reported CTD structures. The Phe853 side chain again stacks over the terminal base pair in the RNA. The dsRNA 
adopts an A form conformation, with no evidence of destabilization or partial unwinding. The RNA-binding 
interface involves at least three separate domains. RIG-I undergoes large ATP-driven conformational changes 
upon binding to dsRNA, with the dsRNA providing a template for RIG-I domain assembly [234].
The crystal structure of RIG-I(Δ-CARD) bound to a designed RNA hairpin containing a 5′-PPP and ADP is 
similar to the RIG-I:dsRNA structure described above (Fig. 42a) [238]. The RNA contains a 5′-triphosphate and 
a stem of 8 bp that is linked by a UUCG tetra-loop, an arrangement that mimics the panhandle-like structures 
formed by the genomes of many negative-stranded RNA viruses. The structure is likely to be biologically 
Fig. 40 (a) Structure of RIG-I CTD bound to blunt-end 5′-PPP 12-mer ds-RNA. (b) Interactions between the 5′-PPP and the CTD. 
Phosphates are yellow/red. The Phe853 side chain, which stacks with the bases of the terminal base pair, is highlighted.
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relevant since the RNA stimulates efficient ATP hydrolysis by RIG-I. The CTD now encapsulates the 5′-PPP at 
the duplex terminus through a network of electrostatic interactions involving K861, K888, K858, and H847 
(Fig. 42b). The α and β phosphates at the 5′ terminus are particularly critical for RIG-I binding, which together 
with the favorable π–π stacking of F853 side chain onto the terminal base pair, helps RIG-I to select the 
correct pathogenic RNA from the vast pool of capped cellular RNAs. The γ-phosphate does not form direct 
contacts with the protein, suggesting that it is not a major recognition determinant. The position of the bound 
nucleotide (ADP) was identified within conserved ATPase motifs in HEL1. HEL2 is not involved in RNA or ADP 
binding, however, the HEL2i domain again makes an extensive contact interface with the RNA duplex. The 
UUCG tetra-loop at the other hairpin terminus is absorbed into an RNA-binding funnel and does not establish 
any base-specific contacts with RIG-I. The phosphates of ADP are bound to RIG-I through a bridging Mg2+.
Fig. 41 (a) Domain organization of the RIG-I protein. The boxed region (ΔCARDs) was crystallized. (b) Overall structure of the 
RIG-I dsRNA complex. The domain coloring is that shown in A. C, Solvent accessible protein surface of the complex.
Fig. 42 (a) Ternary complex of RIG-I (ΔCARDs), 5′-PPP hairpin-RNA and ADP-Mg2+. (b) Interactions between the 5′-PPP and the 
CTD. Phosphates are yellow/red. In the hairpin RNA, G1 base pairs with C20.
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A comparison of available RIG-I:nucleotide structures indicates that the helicase domain is in an open 
conformation in the absence of RNA substrate [235–237]. In the presence of RNA and the ATP analogue ADP-
AlF3, the helicase domain adopts a closed conformation (Fig. 43). In the complex with ADP-Mg2+, the product 
of ATP hydrolysis, RIG-I adopts an intermediate semi-closed state. The RIG-I conformation thus appears to 
be very sensitive to ATP binding, hydrolysis, and product release. This leads to a model for RIG-I signaling, 
where after RNA binding, ATP hydrolysis moves the CTD and HEL2i domains in opposite directions, which 
likely allows the CARDs to be released from HEL2i into a position where they can signal to downstream mol-
ecules (Fig. 43) [238].
5.2  RNA recognition by MDA5
MDA5 is a second cytoplasmic viral RNA receptor, which shares high sequence similarity to RIG-I, and inter-
acts with a common signaling adapter MAVS, which activates interferon signaling pathways [239]. However, 
these sensors recognize largely distinct groups of viruses and viral RNAs. MDA5 detects long-duplex RNAs 
in the genome of dsRNA viruses or dsRNA replication intermediates of positive strand viruses. Neverthe-
less, MDA5 and RIG-I have similar domain architectures, with N-terminal CARD domains that interact with 
MAVS, a central helicase domain for RNA-dependent ATP hydrolysis, and a C-terminal domain (CTD) (Fig. 4). 
However, the CTD of MDA5 displays affinity for dsRNA that is orders of magnitude lower than that of full-
length MDA5, suggesting different mechanisms of dsRNA recognition by RIG-I and MDA5 [240].
MDA5 forms a higher-order structure during RNA recognition and signaling, by cooperatively assem-
bling into a filamentous oligomer composed of a repeating segmental arrangement of MDA5 dimers along 
the length of dsRNA [240]. Binding of MDA5 to dsRNA stimulates ATP hydrolysis, which stimulates assembly 
and disassociation of MDA5 from dsRNA in a manner inversely proportional to the filament length. Thus, ATP 
Fig. 43 (a) Structure of duck RIG-I-Hel (lacking CARDs and CTD domains) in an open conformation (PDB 4A2P), in which the 
HEL1 and HEL2 domains are not in direct contact [236]. In full-length RIG-I, the CARDs would be linked to the N-terminus of HEL1 
and the CTD to the C-terminus of HEL2 (see Fig. 41a). The bridging or pincer domain comprising two long α-helices connected 
by an ≈80° bend is shown in red. (b) Structure of RIG-I lacking only the CARDs with dsRNA (PDB 2YKG) [237]. The RIG-I protein 
completely surrounds the dsRNA, which is bound in a central cavity. (c) A model for RIG-I activation (adapted from [236] and 
[237]). In the absence of RNA, RIG-I is in an autoinhibited open state. 5′-PPP-RNA is first captured by the CTD. Upon binding and/
or hydrolysis of ATP the activated closed form is generated, competent for signaling through the CARDs.
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hydrolysis has a key role in the control of filament assembly and disassembly, thereby autoregulating the 
interaction of MDA5 with dsRNA, and likely providing a basis for dsRNA length-dependent antiviral signaling.
Recently, a crystal structure was reported of human MDA5 lacking the CARD domains (residues 298–
1018), an internal loop (residues 645–662) and the C-terminal tail (residues 1018–1025) [241]. These deletions 
do not affect RNA-binding affinity or ATP hydrolysis activity of the MDA5, but afforded crystals of the protein 
(MDA5ΔN′) complexed to a 12 bp dsRNA and an ATP analog [5′-adenyl-β-imidodiphosphate (ADPNP)].
The structure of the ternary complex reveals that MDA5ΔN′ forms a ring-like structure around the 12 bp 
dsRNA (Fig. 44). MDA5 makes contact with the dsRNA using the HEL1, Hel2i, Hel2, and CTD domains, but 
not the pincer (P) domain. Most protein residues interact primarily with the RNA phosphate backbone and 
2′-hydroxyl groups, consistent with sequence-independent recognition of dsRNA. Mutational studies suggest 
that all domains make important contributions to high-affinity dsRNA recognition [241]. Similar interac-
tions are found upon RNA binding to RIG-I, with the exception of interactions involving the CTD. The bound 
ADPNP is located in a cleft between HEL1 and HEL2, in the outer rim of the MDA5 ring structure. A structurally 
similar binding site for the nucleotide is found in RIG-I.
A major difference between MDA5 and RIG-I is seen in the orientation of the CTD [241]. Whereas in RIG-I 
the CTD encapsulates the 5′-PPP end of the RNA, in the complex with MDA5 the CTD (residues 900–1017) is 
oriented differently so that it makes contact to the side of the dsRNA (Fig. 45). This difference in CTD orienta-
tion results in an open, C-ring-shaped structure of MDA5 that binds to the stem of dsRNA, as opposed to the 
O-ring structure formed by RIG-I, which caps the dsRNA end. On the other hand, the conformation of the 
helicase domain is well preserved between RIG-I and MDA5 (Cα RMSD 1.9 Å). In both complexes with RNA, 
the CTDs form an extensive interaction with HEL2i, with buried surface areas of ≈510 Å2. The convex surface 
of the Zn-binding site in the CTD is complementary to the concave face of HEL2i. Interestingly, a surface loop 
in HEL2 (residues 758–767) of MDA5 inserts into the major groove of the bound dsRNA stem, whereas in RIG-I 
the equivalent loop binds to the end of the RNA (Fig. 45). In the MDA5-dsRNA complex, the major groove is 
widened from 1.2 to 1.8 nm at the site of the HEL2 loop insertion, but the interaction between the inserted loop 
and dsRNA is limited to the phosphate backbone and does not lead to sequence-dependent base recognition. 
A ΔHEL2-loop mutant, however, still bound strongly to dsRNA, but lacked the dsRNA-dependent ATP hydrol-
ysis activity. Thus, insertion of the HEL2 loop into the major groove seems to be important for ATP hydrolysis 
and subsequent signaling. Overall, close interaction between the helicase domain and the CTD provides the 
molecular basis for the divergent RNA specificity of MDA5 and RIG-I.
EM studies have revealed that MDA5 rings bind and stack along dsRNA to form filamentous oligomers 
[240, 242, 243]. Structural models of the filaments have been built using both EM and crystallographic results. 
Fig. 44 Structure of the MDA5ΔN′ protein bound to dsRNA (PDB 4GL2) [241]; left, top view; right, side view. The domains are 
colored as in Fig. 4. The MDA5 forms a ring around dsRNA, bound in the central cavity. The position of bound nucleotide ana-
logue ADPNP is indicated.
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High-resolution structural models predict a head-to-tail association of MDA5 subunits in the filaments, a 
repeating unit of ≈14 bp, and a turn of ≈70° between each monomer (Fig. 46) [241]. This arrangement leads 
to a monomer–monomer interface comprising largely the helicase domain, with a total buried surface area 
of ≈1500 Å2. Defining the complete architecture of full-length MDA5, however, requires knowledge of the 
arrangement of the two CARDs within the filament. Biochemical studies have shown that isolated 2CARDs can 
self-oligomerize at high protein concentration. This oligomerization of the CARDS is required to activate the 
downstream signaling molecule MAVS. Favored models of full-length MDA5 within filaments bring the 2CARD 
from each monomer together to form discrete filaments or patches of oligomers along the central MAD5 fila-
ment (Fig. 46) [241]. The size, frequency, and positioning of individual patches are stochastically determined 
during MDA5 filament assembly and ATP hydrolysis. Thus, MDA5 binding to dsRNA, filament formation, and 
additional conformational rearrangements during ATP hydrolysis, appear to be required for efficient oligomer-
ization of the CARDs and interaction with MAVS. ATP hydrolysis does not simply trigger assembly or disassem-
bly of the filament, but is required to allow 2CARD oligomerization and binding to MAVS.
6  Note added in proof
A recent study describes the crystal structure of a fragment derived from mouse NLRC4 [244]. The NLRC4 
inflammasome is activated in mice by bacterial flagellin or the components of type 3 secretion system. In 
another study, the crystal structure was reported of a RIG-I:dsRNA complex. A minimal RNA duplex was 
identified that binds one RIG-I molecule, stimulates robust ATPase activity, and elicits a RIG-I-mediated inter-
feron (IFN) response in cells [245]. Other studies establish a clear role for the ligand-induced ATPase activ-
ity of RIG-I in the stimulation of an IFN response [246]. Finally, new studies suggest that RNA:DNA hybrids 
arising during viral replication are a novel molecular pattern sensed by TLR9 [253], and that TLR10 in humans 
is involved in induction of innate immune responses to influenza infection [254].
Fig. 45 (a) Top view of the MDA5ΔN′-dsRNA complex showing the extensive interactions between HEL2i and CTD (HEL1 and 
HEL2 are gray, pincer domain red). (b) The HEL2i-CTD interface with bound Zn2+. (c) Left, the HEL2 loop (red) in MDA5ΔN′ 
is inserted into the major groove of dsRNA, which widens from 1.2 to 1.8 nm. Right, the RIG-I loop binds to the end of the 
5′-PPP-RNA.
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Fig. 46 Oligomerization of full-length MDA5 on long dsRNA. Three models for the oligomers (I, II, and III) that are consistent 
with experimental data. In the first two models, 2CARDs form a filament along or around the central MAD5 filament. Alterna-
tively, 2CARDs may form discrete patches along the central MAD5 filament. Adapted from [241].
Table 1 Structures of pattern recognition receptors and complexes with PAMPs available in the protein database (PDB).
PRR   Source   Resol. ( × 10 nm)  PDB code   Reference
TLR1/2   human TLR1-TLR2 + Pam3CSK4 complex   2.10  2Z7X  [74]
  mouse TLR2 dimer with Pam3CSK4 or Pam2CSK4   1.80  2Z81  [74]
    2.60  2Z82 
TLR2   mouse TLR2 with PE-DPTA or pn-LTA   2.4  3A76  [75]
    2.5  3A7B 
TLR2/6   mouse TLR2-TLR6 + Pam2CSK4   2.9  3A79  [75]
CD14   mouse CD14   2.5  1WWL  [128]
  human CD14   4.0  4GLP  [127]
TLR3   human TLR3   2.4  2A0Z  [78]
    2.1  1ZIW  [77]
  mouse TLR3 alone and with dsRNA   2.66  3CIG  [80]
    3.41  3CIY 
MD2   human MD-2 aloneand with lipid IVa   2.00  2E56  [143]
    2.21  2E59 
TLR4/MD-2   mouse TLR4 with MD-2 and bound endotoxin   2.84  2Z64  [102]
  human TLR4 with MD-2 and bound LPS   3.10  3FXI  [144]
  mouse TLR4/MD-2 with lipid-IVa   2.70  3VQ1  [148]
  with LPS   2.48  3VQ2 
FliC   Salmonella sp. flagellin   2.00  1IO1  [149]
TLR5   zebra fish TLR5   2.83  3V44  [83]
  TLR5 with flagellin   2.47  3V47 
TLR8   human TLR8, unliganded   2.30  3W3G  [160]
  hTLR8 with CL097   2.00  3W3J  [160]
  hTLR8 with CL075   2.30  3W3K 
  hTLR8 with R848,   2.33  3W3L 
  3 forms   2.70  3W3M 
    2.10  3W3N 
DC-SIGN   human DC-SIGN and DC-SIGNR CRD with bound sugar 5mer  2.50  1K9I  [188]
DC-SIGNR     1.90  1K9J 
  DC-SIGN + Man4   1.55  1SL4  [189]
  DC-SIGN + LNFP-III   1.80  1SL5 
  DC-SIGN + Lewisx   2.25  1SL6 
  DC-SIGN + Man6   2.40  2IT5  [190]
  DC-SIGN + Man2   1.95  2IT6 
  DC-SIGNR neck region   2.25  1XAR  [185]
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PRR   Source   Resol. ( × 10 nm)  PDB code   Reference
    1.41  1XPH  [186]
  DC-SIGNR neck region   2.20  3JQH  [187]
Langerin   apo-human Langerin   2.50  3P7F  [193]
  Langerin + disaccharide   2.30  3P7H 
  Langerin + mannose   1.50  3P7G 
Mannose-binding 
proteins (lectins)
  rat MBL CRD + neck   1.80  1RTM  [199]
  hMBL CRD + neck   2.50  1HUP  [198]
  rat MBP CRD   2.30  1MSB  [248]
  rat MBP-A + mannose   1.70  2MSB  [200]
  rat MBP-A CRD   1.80  1YTT  [249]
  rat MBP-C + sugars   1.70  1RDO  [201]
    1.80  1RDN 
    1.90  1RDM 
    1.70  1RDL 
    1.80  1RDK 
    1.80  1RDJ 
    1.80  1RDI 
  MBP-A + galactose   2.00  1AFA  [204]
    1.90  1AFB 
    2.00  1AFD 
  MBP-A + Lewisx oligos   2.10  1KMB  [250]
    2.00  2KMB 
    1.95  3KMB 
    2.00  4KMB 
  rat MBP-C   1.85  1BV4  [251, 252]
    1.90  1BUU 
  rat MBP-C + GalNAc   2.10  1BCJ  [203]
    2.00  1BCH 
  rat MBP-A   1.95  1KWT  [202]
  +αMe-O-Man   1.95  1KWU 
  +αMe-O-GlcNAc   2.00  1KWV 
  +αMe-O-Fuc   1.90  1KWW 
  +βMe-O-Fuc   2.00  1KWX 
  +Manα1-3Man   2.00  1KWY 
  H189V + Manα1-3Man   1.90  1KWZ 
  H189V/I207V + Manα1-3Man   2.00  1KX0 
  +Man6GlcNAc2Asn   2.80  1KX1 
  rat MBP-C + Manα1-3Man   1.74  1KXA 
  + Manα1-3[Manα1-6]Man   1.80  1KXB 
  + Manα1-2Manα1-6Man   1.85  1KXC 
  + GlcNAcβ1-2Manα1-3[GlcNAcβ1-2Manα1-6]-Man   1.90  1KZD 
  + N-Ac-Tyr-Asp-[Gly-Gly-NH-(CH2)6-O-Man]2   1.80  1KZE 
Mannose receptor  human MR CTLD4   2.30  1EGG  [205]
    2.30  1EGI 
  mouse MR Cys-rich domain   1.70  1DQG  [206]
  +GalNAc-4-SO4   2.20  1DQO 
  +3-SO4-Lewisa   2.20  1FWV  [207]
  +3-SO4-Lewisx   1.90  1FWU 
NODs   human NRLX1   2.65  3UN9  [59]
RLRs   human RIG-I CTD   3.00  2QFB  [230]
      2QFD 
    NMR  2RMJ  [231]
  +5′-ppp dsRNA   2.55  3NCU  [232]
    2.60  3LRN  [233]
    2.15  3LRR 
  hRIG-I (ΔCARD) + dsRNA   2.50  2YKG  [237]
  +dsRNA + ADP   2.58  4BPB 
  ATPase domain of RIG-I   2.80  4AY3  [238]
(Table 1 Continued)
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PRR   Source   Resol. ( × 10 nm)  PDB code   Reference
  +AMP-PNP   2.14  TBK2  [234]
  duck RIG-I CTD   1.44  4A2V 
  dRIG-I helicase   3.00  4A2P  [236]
  dRIG-I CARDs + helicase   3.40  4A2Q 
  dRIG-I full length   3.70  4A2W 
  dRIG-I CTD + dsRNA   4.00  4A2X 
  dRIG-I + dsRNA + ADP-AlF3   3.70  4A36 
  hRIG-I + dsRNA + BeF3   2.90  3TMI  [235]
MDA5   human MDA5 + dsRNA   3.56  4GL2  [241]
7  Abbreviations
APC antigen-presenting cell
BCR B-cell receptor
BIR baculovirus inhibitor repeat
CARD caspase activation and recruitment domain
CIITA class II transactivator
CRD carbohydrate recognition domain
CTD C-terminal domain
CTL C-type lectin
CTLD C-type lectin (or lectin-like) domain
CTLR C-type lectin receptors
DC dendritic cell
DC-SIGN(R)  dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin (and the R 
variant)
DTPA 1,2-dimyristoyl-sn-glycero-3-phospho-ethanolamine-N-diethylenetriaminepentaacetic acid
ECD extracellular domain
FliC flagellin
FNII fibronectin type II
GPI glycosyl-phosphatidyl-inositol
IFN interferon
IRF interferon-regulated factor
HEL1 helicase domain 1
LBP LPS binding protein
LGP2 laboratory of genetics and physiology 2
LNFP-III lacto-N-fucopentaose-III
LPS lipopolysaccharide
LRR leucine-rich repeat
LTA lipoteichoic acid
MBP mannose-binding protein
MHC-I and -II major histocompatibility complex-I and -II
MDA5 melanoma differentiation associated factor gene 5
MPL monophosphoryl lipid A
MR mannose receptor
MLS macrolide-lincosamide-streptogramin group
NACHT a conserved domain found in NAIP, CIITA, HET-E, and TPI-1
NAIP NLR family apoptosis inhibitory protein
(Table 1 Continued)
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NK natural killer
NLR NOD-like receptor
NOD nucleotide-binding and oligomerization domain
ODN oligodeoxynucleotide
OM outer membrane
PAMP pathogen-associated molecular pattern
PE phosphatidyl-ethanolamine
PGN peptidoglycan
PPI protein–protein interface
PRR pattern recognition receptor
PYD pyrin domain
RIG retinoic acid-inducible gene-I
RLR RIG-like receptor
TIR  Toll IL-1 receptor
TLR Toll-like receptor
VLR variable lymphocyte receptor
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